[go: up one dir, main page]

EP1003748A2 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase - Google Patents

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Info

Publication number
EP1003748A2
EP1003748A2 EP98951348A EP98951348A EP1003748A2 EP 1003748 A2 EP1003748 A2 EP 1003748A2 EP 98951348 A EP98951348 A EP 98951348A EP 98951348 A EP98951348 A EP 98951348A EP 1003748 A2 EP1003748 A2 EP 1003748A2
Authority
EP
European Patent Office
Prior art keywords
pyrrolo
hexahydro
methanesulfonyl
carbonyl
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98951348A
Other languages
German (de)
French (fr)
Inventor
Geoffrey Duke Edward Clarke
Michael Dennis Dowle
Harry Finch
Lee Andrew Harrison
Graham George Adam Inglis
Martin Redpath Johnson
Simon John Fawcett Macdonald
Pritom Shah
Robin Andrew Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9719183.7A external-priority patent/GB9719183D0/en
Priority claimed from GBGB9719189.4A external-priority patent/GB9719189D0/en
Priority claimed from GBGB9719290.0A external-priority patent/GB9719290D0/en
Priority claimed from GBGB9803611.4A external-priority patent/GB9803611D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1003748A2 publication Critical patent/EP1003748A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to therapeutically active bicyclic compounds, processes for their manufacture, pharmaceutical formulations containing them and their use in chemotherapy.
  • novel bicyclic compounds which are effective in treating inflammatory diseases.
  • Inflammation is a primary response to tissue injury or microbial invasion and is characterised by circulating leukocytes binding to and extravasation through vascular endothelium. Circulating leukocytes include neutrophils, eosinophils, basophils, monocytes and lymphocytes. Different forms of inflammation involve different types of infiltrating leukocytes.
  • the inflammatory process can be triggered in a number of ways, including by infection, tissue damage and autoimmune reactions.
  • neutrophils move from the bloodstream into the tissue at the site of tissue lesion.
  • the neutrophils contain large numbers of different intracellular granules and when activated at the site of inflammation the contents of these granules are secreted into the tissue.
  • the different granules contain a variety of enzymes and other proteins, many of which have antibacterial properties.
  • neutrophil elastase One of the enzymes found in the azurophilic granules is neutrophil elastase.
  • Neutrophil elastase has a wide spectrum of activities in the body. For example, within the lung the enzyme increases mucus production and changes the cellular composition of the epithelium The enzyme also causes vascular permeability changes within the microcirculation of many tissues and it is a potent destructive agent against a number of connective tissue components.
  • elastase activity has been implicated in the pathogenesis of a number of disease states including inflammatory diseases of the airways, the joints and the skin.
  • the enzyme is also responsible for some or most of the symptoms of acute respiratory distress syndrome (ARDS) and other acute inflammatory states brought about by trauma and/or sepsis.
  • ARDS acute respiratory distress syndrome
  • R 1 represents C 1-6 alkyl
  • R 2 represents C 2-4 alkyl or C 2- alkenyl
  • X represents CO or SO 2 ;
  • Het represents an optionally substituted 5 to 10 membered monocylic or bicyclic aromatic ring system containing 1 to 4 heteroatoms selected from O, N and S; n represents an integer 0 to 4;
  • R 3 and R 4 independently represent hydrogen, C 1-8 alkyl, -(CH 2 ) CONR 5 R 6 , COC ⁇ alkyl or (CH 2 ) 0-2 Ph where Ph represents phenyl optionally substituted by one or more C 1-4 alkyl or halogen groups or NR 3 R 4 together represents azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, morpholinyl, piperazinyl optionally N- substituted by C 1-6 alkyl, phenyl (optionally substituted by halogen or C 1-4 alkyl) or benzyl (optionally substituted on the benzene ring by halogen or C 1-4 alkyl) or NR 3 R 4 together represents a ring as just described save that it is substituted on carbon by one or more C ⁇ alkyl, CONR 5 R 6 or COOR 6 groups; R 5 and R 6 independently represent hydrogen or C 1-4 alkyl; and salts and solvates thereof
  • Formula (I) shows the relative stereochemistry of the chiral centres.
  • the invention embraces compounds of the invention in racemic form as well as in a form in which one enantiomer predominates or is present exclusively.
  • the present invention also covers the physiologically acceptable salts of the compounds of formula (I).
  • physiologically acceptable salts of the compounds of formula (I) include inorganic and organic acid salts such as hydrochloride and tartrate.
  • alkyl includes branched as well as straight chain alkyl and may also include cycloalkyl when 3 or more carbon atoms are present.
  • Suitable R ⁇ alkyl groups include methyl, ethyl and propyl.
  • Het groups include furanyl, imidazolyl, thiophenyl, pyrrolyl, thiazolyl, isoxazolyl, pyrazolyl, pyridinyl and pyrazinyl.
  • Het may be connected to the pyrrolidine ring via X in any position.
  • connectivities include furan-2-yl, furan-3-yl, imidazol-2-yl, imidazol-4-yl, thiophen-2-yl, pyrrol-2-yl, thiazol-4-yl, isoxazol-3-yl, pyrazol-3-yl, pyrazol-5-yl, pyridin-3-yl, l-methyl-pyrrol-2-yl, 1-methyl-pyrazol-3-yl, 1-methyl-pyrazol-5-yl and pyrazin-2-yl.
  • substituents for Het include C 1-6 alkyl (e.g. methyl, ethyl), C ⁇ alkoxy (e.g. methoxy), nitro and halogen (e.g. chlorine, bromine, fluorine, iodine).
  • the substituent(s) may be on carbon or nitrogen.
  • substituted Het examples include 1 -methyl pyrrolyl, 1 -methyl pyrazolyl.
  • positions for the sidechain shown in formula (I) include for furan-2- yl the 5 position, for furan-3-yl the 2 position, for thiophen-2-yl the 5 position, for pyrrol-2-yl the 4 or 5 position, for 1 -methyl pyrrol-2-yl the 5 position, for thiazol-4- yl the 2 position, for isoxazol-3-yl the 5 position, for 1-methyl-pyrazol-3-yl the 5 position, for 1-methyl-pyrazol-5-yl the 3 position, for pyridin-3-yl the 6 position and for pyrazin-2-yl the 5 position.
  • R 3 and R 4 independently represent C 1-8 alkyl, examples include methyl, ethyl, cyclopropyl, n-propyl, isopropyl, n-butyl, CH(iPr) 2 and cyclohexyl.
  • R 3 and R 4 independently represent (CH 2 ) 0-2 Ph, examples include phenyl, benzyl and (4-F-phenyl)methyl.
  • NR 3 R 4 together represents N-substituted piperazinyl, examples include N- phenyl-piperazinyl and N-methyl-piperazinyl.
  • NR 3 R 4 When NR 3 R 4 together represents a ring substituted on carbon, examples of substituents include methyl, CONH 2 and COOMe. Examples of such NR 3 R 4 include 4-methyl piperidin-1-yl.
  • R 1 to represent methyl or ethyl, especially methyl.
  • R 2 to represent isopropyl or propyl, especially isopropyl.
  • Het to represent a 5 or 6 membered monocyclic aromatic ring containing 1 or 2 heteroatoms selected from O, N and S which is more preferably thiazolyl, isoxazolyl, pyrazolyl or pyrazinyl, especially thiazolyl (particularly thiazol-4-yl) or pyrazinyl.
  • Het to represent pyridinyl, especially 3-pyridinyl.
  • Het represents pyrazinyl.
  • Het represents pyrazin-2-yl in which the sidechain is in the 5-position.
  • Het to represent oxazolyl, particularly oxazol-4-yl.
  • n represents 1 to 3, particularly 1 or 2, especially 1.
  • R 3 and R 4 independently to represent hydrogen or C h alky! or for NR 3 R 4 to represent pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl optionally N-substituted by C 1-8 alkyl or phenyl (optionally substituted by halogen or C 1-4 alkyl).
  • preferred NR 3 R 4 groups are NMe 2 , N(n-butyl) 2 , NHMe NH(cyclopropyl), NHCH(iPr) 2 and N(cyclohexyl) 2.
  • a set of compounds of formula (I) of particular interest are compounds of formula (IA) in which Het represents oxazol-4-yl with the sidechain in the 2- position:
  • X to represent CO.
  • R to represent isopropyl or propyl, especially isopropyl.
  • R 1 to represent methyl or ethyl, especially methyl.
  • n to represent 1 to 3, particularly 1 or 2, especially 1.
  • R 3 and R 4 independently to represent hydrogen or C ⁇ alkyl or for NR 3 R 4 to represent pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl optionally N- substituted by C 1-8 alkyl or phenyl (optionally substituted by halogen or C 1-4 alkyl).
  • -NR 3 R 4 to represent pyrrolidinyl, piperidinyl, N- phenylpiperazinyl, N(butyl) 2 , NMe(cyclopropyl) or N(cyclohexyl) 2 , most particularly pyrrolidinyl.
  • the potential for compounds of the invention to inhibit neutrophil elastase activity may be demonstrated, for example, using the following in vitro and in vivo assays:
  • Suitable concentrations of compound under test diluted with water from a 10mM stock solution in dimethylsulphoxide are final concentrations after the addition of substrate solution (see below).
  • Enzyme activity is plotted against concentration of inhibitor and an IC50 determined using curve fitting software.
  • Intracellular elastase is prepared from neutrophils collected by lavage and from femoral bone marrow . This is achieved by sonication of the neutrophils and centrifugation to yield intracellular granules. These are disrupted by freeze/thawing and sonication. Elastase and myeloperoxidase assays are then performed on these samples to assess the efficacy of the compounds and to normalise for neutrophil recovery.
  • the wash is with saline (300 ⁇ l), followed by centrifugation at 100g for 10 minutes at 4°C. Pellets are washed twice more, before resuspension of the final cell pellet in buffer (200 ⁇ l of 100mM Tris, 300mM NaCI, 1% (w/v) HTAB, pH 8.6). Samples are stored at -20 °C. After freeze-thawing of the samples four times, elastase activity is determined by a colorimetric assay in 50mM Tris, 150mM NaCI, 0.6mM MeO-Succ-Ala-Ala-Ala-Pro-Val-pNA at pH 8.6, measuring the rate of increase in absorbance at 405nm.
  • the compounds of the invention are of potential therapeutic benefit in the treatment and amelioration of symptoms of diseases where elastase activity is implicated.
  • diseases particularly include bronchitis, including chronic bronchitis. Also any chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Examples of disease states in which the compounds of the invention have potentially beneficial effects include inflammatory diseases of the respiratory tract such as bronchitis (including chronic bronchitis), bronchiectasis, asthma and hyper-reactivity states of the lung, acute respiratory distress syndrome and septic shock, inflammatory or destructive conditions of the lung such as emphysema and cystic fibrosis and inflammatory or destructive conditions of external tissue such as skin diseases (e.g. lupus and psoriasis) and periodontal disease including gingivitis.
  • inflammatory diseases of the respiratory tract such as bronchitis (including chronic bronchitis), bronchiectasis, asthma and hyper-reactivity states of the lung, acute respiratory distress syndrome and septic shock, inflammatory or destructive conditions of the lung such as emphysema and cystic fibrosis and inflammatory or destructive conditions of external tissue such as skin diseases (e.g. lupus and psoriasis) and periodontal disease including ging
  • cardiovascular diseases such as myocardial infarction and stroke, peripheral vascular disease including intermittent claudication, atherosclerosis, reperfusion injury, cardiovascular changes occurring during cardiopulmonary bypass surgery and septicemia.
  • Compounds of the invention may also be useful in the treatment of connective tissue disorders such as rheumatoid arthritis, osteoarthritis and spondylitis and inflammatory conditions of the kidney such as glomerulonephritis. They may also be useful in the treatment of certain leukemias including acute myelogenous leukemia, acute myelomonocytic leukemia and the chronic monocytic leukemias and in prevention or inhibition of metastasis of solid tumours e.g. lung, breast, prostate and stomach cancers and melanomas.
  • a particular aspect of the present invention is the use of compounds of formula (I) in the treatment of chronic bronchitis.
  • Chronic bronchitis is a condition which results from the exposure of the airway surface to noxious chemicals or agents or is secondary to another disease. The symptoms of the condition are caused by the excessive secretion of mucus onto the surface of the airways. This excess mucus cannot be cleared effectively and the result is reduced gas exchange within the lungs resulting in laboured breathing and hypoxemia, recurrent microbial infections and persistent cough associated with the expectoration of mucoid material.
  • the proposed mechanism for the excessive secretion of mucus involves the recruitment of neutrophils into the airways following the exposure of the epithelium to irritant materials; the neutrophils secrete elastase onto the surface of the airways and the enzyme brings about both an increase in the amount of mucus secreted onto the airway surfaces and a dramatic change in the cellular composition of the airway epithelium.
  • Inhibition of elastase activity by the administration of compounds of this invention is therefore an approach to the treatment of chronic bronchitis.
  • Reduced lung function in COPD eg in chronic bronchitics with airflow obstruction
  • an elastase inhibitor will improve lung function.
  • compounds of the invention are useful in human or veterinary medicine, in particular as inhibitors of the enzyme neutrophil elastase.
  • a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in human or veterinary medicine, particularly in the treatment of conditions where elastase activity is implicated such as chronic bronchitis.
  • references herein to treatment extend to prophylaxis as well as the treatment of established conditions.
  • a compound of formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of conditions where elastase activity is implicated, particularly in chronic bronchitis.
  • a method for the treatment of a human or animal subject with a condition caused or mediated by elastase activity comprises administering to said human or animal subject an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.
  • compositions for use in therapy comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof in admixture with one or more physiologically acceptable diluents or carriers.
  • composition which comprises mixing the ingredients.
  • the compounds according to the invention may, for example, be formulated for oral, buccal, parenteral, topical or rectal administration.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disinteg rants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl £- hydroxybenzoates or sorbic acid.
  • the preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds according to the invention may also be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative.
  • the compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or toxicity adjusting agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • the dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.
  • topical administration as used herein, we include administration by insufflation and inhalation.
  • preparation for topical administration include ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents.
  • bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol.
  • Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
  • Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.
  • Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1 ,1 ,1,2,3,3,3-heptafluoropropane, 1 ,1 ,1,2- tetrafluorethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1 ,1 ,1,2,3,3,3-heptafluoropropane, 1 ,1 ,1,2- tetrafluorethane, carbon dioxide or other suitable gas.
  • Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents such as corticosteroids or NSAIDs, bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline), mucolytic agents, anti- muscarinics, anti-leukotrienes, inhibitors of cell adhesion (e.g. ICAM antagonists), anti-oxidants (eg N-acetylcysteine), lung surfactants and/or antimicrobial and anti-viral agents.
  • anti-inflammatory agents such as corticosteroids or NSAIDs
  • bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline)
  • mucolytic agents e.g. theophylline
  • anti-muscarinics e.g. theophylline
  • anti-leukotrienes e.g. the
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof represent a further aspect of the invention.
  • the compound of the invention may conveniently be administered in amounts of, for example, 0.01 to 50mg/kg body weight, suitably 0.05 to 25mg/kg body weight orally, one or more times a day.
  • the precise dose will of course depend on the age and condition of the patient, the particular route of administration chosen, and the disease being treated.
  • the compound is preferably administered orally for the treatment of bronchitis. Other routes of administration may be needed for other indications, for instance i.v. for ARDS.
  • the compounds of the invention have useful duration of action.
  • a process according to the invention for preparing a compound of formula (I) comprises:
  • the condensation reaction with R 4 R 3 N(CH 2 ) n HetCOOH is suitably carried out in the presence of a coupling agent such as 1-(3-N,N-dimethylaminopropyl)-3- ethylcarbodiimide, preferably also in the presence of HOBT, and a solvent such as dichloromethane, DMF, MeCN or tetrahydrofuran at a temperature of suitably between O°C and ambient.
  • a coupling agent such as 1-(3-N,N-dimethylaminopropyl)-3- ethylcarbodiimide
  • HOBT preferably also in the presence of HOBT
  • a solvent such as dichloromethane, DMF, MeCN or tetrahydrofuran
  • reaction conditions will be modified accordingly, for instance by inclusion of a base. If one or both of R 3 , R 4 represents hydrogen, it will generally be preferred to protect the nitrogen, e.g. with BOC.
  • reaction is suitably carried out in the presence of a base such as triethylamine and a solvent such as DCM, suitably at 0°C- ambient.
  • a base such as triethylamine
  • a solvent such as DCM
  • the sulphonylation reaction is suitably carried out in the presence of LHMDS or
  • R 3 and R 4 represents hydrogen, it may be necessary to protect the nitrogen, e.g. with BOC.
  • the cyclisation reaction is suitably carried out in the presence of 2-chioro-1- methylpyridinium iodide, or EDC, in a solvent such as dichloromethane, at a temperature of suitably 0°C - reflux.
  • This reaction may also be performed using a carboxylic acid thioester derivative of the compound of formula (IV).
  • another acid derivative such as an acid halide (e.g. acid chloride) may be used.
  • This oxidation reaction may be carried out in conventional manner such as by peracid oxidation.
  • Preferred leaving groups include halogen (such as chlorine, bromine or iodine), mesylate and tosylate.
  • the reaction may be performed by combining the reactants optionally in the presence of a base such as triethylamine or potassium carbonate in an inert solvent such as DMF or MeCN.
  • This reaction will take place on combining the reagents in an inert solvent, e.g. DCM at ambient or elevated temperature.
  • an inert solvent e.g. DCM at ambient or elevated temperature.
  • Reduction can be performed in situ using a conventional mild reducing agent such as NaBH 3 CN or NaBH(OAc) 3 .
  • Process (ix) Purification of a single enantiomer may be achieved by conventional methods such as chiral chromatography (e.g. chiral HPLC) and crystallisation with a homochiral acid (e.g. tartaric acid).
  • Physiologically acceptable acid salts of the compound of formula (I) such as the hydrochloride or tartrate may be prepared by treating a basic compound of formula (I) with the desired acid.
  • BOC may be performed by reacting with (BOC) 2 O in the presence of base (e.g.
  • This conversion may be performed on treatment with ammonium bicarbonate in the presence of a suitable solvent such as pyridine/DMF and in the presence of
  • CBZ may be performed by reaction with nBuLi followed by CBZ-CI in the presence of an inert solvent such as THF below -50 °C.
  • This reaction may be performed by treatment with RX where RX is a compound
  • R e.g. Mel, benzyl iodide or Me 2 SO 4
  • a suitable solvent e.g. propanone or acetonitrile.
  • R will represent alkyl or aralkyi and X will represent halide, especially iodide, or sulphate. Protection of the amide is convenient, although not essential, for this reaction.
  • Step (e) This ring closure reaction may be performed by treatment with Dowex 2 x 8 400 mesh OH " resin in a suitable solvent, e.g. MeCN.
  • the ring closure may be performed by treatment with potassium carbonate in a suitable solvent, e.g. MeCN.
  • Deprotection may be performed in a conventional manner, for example, a BOC protecting group may be removed by treatment with HCI, e.g. in dioxan.
  • This reaction may be performed by treatment with a trifluoroacetic acid alkyl ester (e.g. the methyl ester) or trifluoroacetic anhydride in the presence of a suitable base e.g. N-methylmorpholine.
  • a trifluoroacetic acid alkyl ester e.g. the methyl ester
  • a suitable base e.g. N-methylmorpholine.
  • This conversion will take place on treating the compound of formula (XV) with a reducing agent e.g. lithium borohydride, followed by treatment with concentrated sulphuric acid in the presence of an alkyl alcohol e.g. ethanol solvent.
  • a reducing agent e.g. lithium borohydride
  • concentrated sulphuric acid in the presence of an alkyl alcohol e.g. ethanol solvent.
  • the reaction of compounds of formula (XVI) and (XVII) takes place in the presence of a Lewis acid e.g. boron trifluoride dietherate and an inert solvent e.g. dichloromethane or MeCN.
  • a Lewis acid e.g. boron trifluoride dietherate
  • an inert solvent e.g. dichloromethane or MeCN.
  • the group "alkyl" in Oalkyl and OSi(alkyl) 3 generally represents C 1-6 alkyl.
  • suitable alkyl groups in the silyl alkyl moiety include methyl, isopropyl and t-butyl.
  • Preferred Oalkyl is OEt and preferred OSi(alkyl) 3 is OSi(i-Pr) 3 or OSi(Me) 2 (t-Bu).
  • the use of variants of compounds of formula (XVII) in which Oalkyl is replaced by OSi(aIkyl) 3 is also envisaged.
  • Compounds of formula (XVII) may be prepared by treatment of the corresponding carboxylic acid ester (R 2 CH 2 COOEt or another alkyl ester, which compounds are either known or may be prepared by known methods) with a strong base (eg LHMDS) followed by a trialkylsilylchloride (such as trimethylsilylchloride) or a trialkylsilyltriflate.
  • a strong base eg LHMDS
  • a trialkylsilylchloride such as trimethylsilylchloride
  • a trialkylsilyltriflate Typically the reaction will be performed at low temperature (less than 0 °C) in an inert solvent (such as THF) in the presence of DMPU.
  • Step (j) This deprotection reaction will take place on treatment with base, such as potassium carbonate.
  • This ring closure reaction may be performed on treatment with an alkyl Grignard reagent (e.g. t-butylmagnesium choride) in an inert solvent such as THF in the presence of tetramethylethylenediamine at a temperature of -20°C to 25°C.
  • an alkyl Grignard reagent e.g. t-butylmagnesium choride
  • an inert solvent such as THF
  • Step (m) This is a N-deprotection reaction, which can suitably be carried out in conventional manner.
  • P. is CBZ
  • it is suitably carried out by hydrogenation over Pd (OH) 2 catalyst in solvents such as ethyl acetate or THF.
  • R 13 is suitably a C 1-6 alkyl group, preferably methyl.
  • the cyclisation reaction will take place on stirring in water with Dowex 2X8 (preferably 400 mesh).
  • the TFA protected amine is formed by treating the compound of formula (XXIV) with methyl trifluoroacetate in a polar protic solvent, eg MeOH.
  • Suitable protecting groups P 1 include CBZ.
  • the compound of formula (XXV) may be treated with a strong base such as LHMDS or nBuLi in an inert solvent such as THF, followed by treatment with CBZ-CI.
  • a strong base such as LHMDS or nBuLi in an inert solvent such as THF
  • the compounds of formula (XXVI) are either known compounds or may be made in analogous manner to known compounds.
  • P- is a N-protecting group, preferably CBZ.
  • Step (a) is a further N-protection reaction.
  • P 2 in formula (XXVII) is a different N-protecting group, preferably BOC. When P 2 is BOC, the reaction is suitably carried out using BOC 2 O.
  • reaction is carried out in the presence of a base such as triethylamine or 4-dimethylaminopyridine in a solvent such as ethyl acetate, at temperature of suitably 0°-25° C.
  • a base such as triethylamine or 4-dimethylaminopyridine
  • a solvent such as ethyl acetate
  • Step (b) This conversion is suitably carried out with pyridinium p-toluenesulfonate, in a solvent such as acetone/water, at a temperature suitably between 25°-75° C.
  • Step (c) This is a condensation rearrangement reaction suitably carried out using a 2- phenylsulfinyl acetic acid ester (PhSOCH 2 CO 2 R 13 ) and piperidine, in a solvent such as acetonitrile, suitably at ambient temperature.
  • a 2- phenylsulfinyl acetic acid ester PhSOCH 2 CO 2 R 13
  • piperidine a solvent such as acetonitrile
  • R 13 is suitably a C 1-6 alkyl group, preferably methyl.
  • THF at a temperature of suitably 0°-40° C.
  • This is a deprotection reaction, preferably using a strong acid such as TFA in a solvent such as DCM, at a temperature of suitably 0°-40° C.
  • R 13 is suitably C 1-6 alkyl, preferably ethyl.
  • a cyclisation reaction suitably carried out as an intramolecular Michael reaction.
  • NaH is used, in a solvent such as THF, at a temperature such as 0° - 25° C.
  • N-deprotection and re-protection two reactions occur: N-deprotection and re-protection.
  • the phthalimido group is removed suitably with hydrazine hydrate in a solvent such as ethanol at a temperature between 0°C and reflux.
  • Protecting group P 3 is incorporated in a conventional manner. When P 3 is BOC, this is suitably achieved with BOC 2 O.
  • the R 2 side chain may be introduced by alkylation, using as reactant R 2 -Y, wherein Y is a reactive group such as bromo or iodo.
  • R 2 -Y wherein Y is a reactive group such as bromo or iodo.
  • the reaction is carried out using a base, preferably a strong base such as LHMDS.
  • LHMDS suitably a cosolvent DMPU in THF is used.
  • Suitable reaction temperatures are -78° to 50°C. Under these conditions the reaction generally takes place with good stereochemical control.
  • the former is carried out in a conventional manner, for example by using KOH in aqueous ethanol, at a temperature of suitably 25°-80°C .
  • the latter is carried out in a conventional manner, for example by using HCI in dioxan, at a temperature of suitably 0°-50°C or, if the protecting group is trifluoroacetate, by treatment with base.
  • a suitable base such as N, N-diisopropyl ethylamine
  • a solvent such as dichloromethane
  • the compounds of formula (XXXVI) are either known compounds or may be 5 prepared in analogous manner to known compounds.
  • P 3 is a protecting group as discussed above, and is suitably BOC.
  • the reaction is suitably carried out using PI FA (phenyl iodosylbis(trifluoroacetate)) and a base such as pyridine in an aqueous solvent, such as aqueous THF, dioxan or acetonitrile. This is the method of Stansfield, C.F. Organic Preparations and Procedures Int., 1990, 10 22(5), 593-603.
  • P ⁇ is a protecting group eg CBZ.
  • This protection reaction may be carried out in a conventional manner. For instance it is suitably carried out in a water miscible solvent such as THF, DMF or dioxan using N-
  • the compound of formula (XXXVIII) can be prepared in conventional manner from diaminobutyric acid.
  • Step (c) This reaction is suitably carried out in two stages.
  • the first stage involves reacting the compound of formula (XXXVIII) at reduced temperature with N- methylmorpholine and then an alkyl chloroformate such as ethyl chloroformate, in an organic solvent such as DCM, dioxan or THF.
  • an alkyl chloroformate such as ethyl chloroformate
  • the product is reduced, suitably with sodium borohydride at reduced temperature, such as -20° to 10°C, in a solvent such as THF.
  • This oxidation reaction may be carried out in any suitable manner, for instance using oxalyl chloride in DMSO and methylene dichloride under nitrogen at reduced temperature, such as -30° to -70°C, followed by triethylamine.
  • the intermediate (XXXX) suitably is not isolated.
  • a phosphonate in a Wadsworth-Emmons reaction.
  • Step (f) This Michael addition reaction is suitably carried out using LHMDS or other strong base in an organic solvent such as THF, ether or toluene, and preferably a complexing agent such as TMEDA is also present.
  • the intermediate compounds of formula (III) may be prepared by reacting a deprotected compound of formula (XX) from Scheme 1 with R 4 R 3 N(CH 2 ) n HetCOOH or R 4 R 3 N(CH 2 ) n HetXY in the manner described above in relation to main process (i) above.
  • the intermediate compounds of formula (IV) may be prepared from a compound of formula (XIX) (with the primary amine suitably protected) in an analogous manner to that described above for preparing a compound of formula (III) from a compound of formula (XX) together with main process (ii) above.
  • Compounds of formula (V) wherein X a represents S may be prepared by reaction of a corresponding compound of formula (III) with a compound of formula R 1 SSR 1 under standard conditions for nucleophilic displacement.
  • Compounds of formula (V) wherein X a represents SO may be prepared by peracid oxidation of a corresponding compound wherein X a represents S.
  • Compounds of formula (VI), (VII) and (VIII) may be prepared from compounds of formula (II) following conventional methods known perse.
  • Mesylate and tosylate derivatives may be prepared from the corresponding alcohol following treatment with MeSO 2 CI or paramethylbenzenesulphonylchloride.
  • Compounds of formula R 4 R 3 N(CH 2 ) n HetCOOH or an acid derivative thereof, and R 4 R 3 N(CH 2 ) n HetXY are either known or may be prepared by conventional methods known perse.
  • Schemes 1 , 2, 3 and 4 may be modified to produce homochiral products by using homochiral starting materials (e.g. S-methionine in Scheme 1 or S-diaminobutyric acid in Scheme 4) or by performing an additional chiral resolution step.
  • homochiral starting materials e.g. S-methionine in Scheme 1 or S-diaminobutyric acid in Scheme 4
  • Both enantiomers of the compound of formula (XIV) may also be produced from a synthesis based on S-methionine or R-methionine following similar procedures.
  • the compounds of the invention have the advantage that they may be more efficacious, show greater selectivity, have fewer side effects, have a longer duration of action, be more bioavailable by the preferred route have more attractive pharmacodynamic or pharmacokinetic properties or have other more desirable properties than similar known compounds.
  • the aqueous phase was extracted with further ethyl acetate (5x250ml), the combined organics were washed with 2M HCI (100ml) and saturated brine solution (100ml), dried (MgSO 4 ), filtered and the solvent evaporated in vacuo to leave a brown solid.
  • the solid was stirred in acetonitrile (900ml) and triethylamine (60ml) and cyclopropylamine (30ml) were added. After stirring for 20 hours at room temperature, further cyclopropylamine (30ml) was added and the mixture stirred for a further 15 minutes.
  • dihydrochloride salts are indicated by the qualification "(2:1)" after the chemical name.
  • Example 1 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1-ylmethyl-furan- 2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • a mixture of Intermediate 11 (80mg) and pyrrolidine (17mg) in dichloromethane (6ml) was stirred for 2h.
  • Sodium triacetoxyborohydride (69mg) was added and stirring was continued overnight.
  • the reaction mixture was washed with 8% aqueous sodium bicarbonate solution and water.
  • Example 5 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-morpholin-4-ylmethyl- furan-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • a mixture of Intermediate 12 (50mg) and morpholine (13mg) in dichloromethane (3.5ml) was stirred for 1.5h.
  • Sodium triacetoxyborohydride (43mg) was added and stirring was continued overnight.
  • the reaction mixture was diluted with dichloromethane and extracted with 2M hydrochloric acid.
  • aqueous extracts were made basic with 8% aqueous sodium bicarbonate solution and extracted with dichloromethane.
  • the dichloromethane extracts were washed with brine, dried (Na 2 SO 4 ) and the solvent removed in vacuo to leave a solid, which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a cream solid (32mg).
  • Example 11 rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-thiophene-2-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • the reaction mixture was diluted with dichloromethane and extracted with 2M hydrochloric acid.
  • the aqueous extracts were washed with dichloromethane then made basic with 2M sodium carbonate solution and extracted with dichloromethane.
  • Example 12 was prepared in a similar manner to Example 11 from Intermediate 13:
  • Example 13 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • the aqueous phase was further extracted with ethyl acetate (30ml).
  • the combined organic phases were dried (Na 2 SO 4 ) and the solvent evaporated in vacuo to leave a gum.
  • Example 15 rel-(3S, 3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1 -ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • Example 16 rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(5-pyrrolidin-1 -ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • Example 17 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-1H-pyrrole-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2) Cream powder, Melting Point 156-160°C
  • Example 23 rel-(3S,3aS,6aR)-4-(5-Dimethylaminomethyl-1-methyl-1H-pyrrole-2-carbonyl)-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • Example 24 rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5-pyrrolidin-1 - ylmethyl-1 H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • Example 26 rel-(3S,3aS,6aR)-4-(4-Dimethylaminomethyl-1 H-pyrrole-2-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • a mixture of Intermediate 14 (80mg), paraformaldehyde (25mg), dimethylammonium chloride (38mg) and activated 4 Angstrom molecular sieves (200mg) in ethanol (10ml) was stirred and heated at reflux for 24h. The mixture was cooled to room temperature and the- solvent was evaporated in vacuo to leave a gum.
  • the gum was purified by flash column chromatography, using two columns (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia; 80:8:1 for the first column, 100:8:1 for the second column) to isolate a white powder (16mg) which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a white powder (16mg).
  • reaction mixture was stirred for 1.5h. An aliquot (7ml) was removed and added to a stirred solution of pyrrolidine (30mg) in dichloromethane (2ml). The solution was stirred for 2 days. Aqueous 8% sodium bicarbonate solution (12ml) was added, with vigorous stirring. The aqueous phase was separated and extracted with dichloromethane (15ml). The organic phases were combined and dried (Na 2 SO ). The solvent was removed in vacuo to leave a semi-solid, which was triturated in diethyl ether (10ml) to give a solid suspension. Cyclohexane (10ml) was added to the suspension and the solvent was decanted.
  • Example 30 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-methyl-piperazin-1- ylmethyl)-thiazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) White powder, Melting Point 153-158°C
  • Example 36 rel-(3S,3aS,6aR)-4-(2-Dimethylaminomethyl-thiazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • Oxalyl chloride (127mg) was added to a stirred suspension of Intermediate 19 (125mg) in dichloromethane (10ml), followed by dimethylformamide (1 drop). The reaction mixture was stirred for 1.0h. then concentrated in vacuo. The residue was suspended in dichloromethane (15ml) and treated, with stirring, with Intermediate 10 (43mg) and sodium bicarbonate (175mg).
  • Example 37 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • a mixture of Intermediate 21 (50mg) and morpholine (13mg) in dichloromethane (5ml) was stirred for 1.5h.
  • Sodium triacetoxyborohydride (43mg) was added and stirring was continued for 2.5h.
  • the reaction mixture was washed with 8% aqueous sodium bicarbonate solution.
  • Example 62 rel-(3R,3aR,6aS)-3-lsopropyl-4- ⁇ 6-[(1-isopropyl-2-methyl-propylamino)-methyl]- pyridine-3-carbonyl ⁇ -1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2)
  • Example 65 rel-(3R,3aR,6aS)-4-(5-Cyclopropylaminomethyl-pyrazine-2-carbonyl)-3- 15 isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • reaction mixture was partitioned between 2M sodium carbonate solution (3ml) and dichloromethane (3ml). The phases were separated. The organic phase was passed through a Varian SPE cartridge (which had been pre-conditioned by eluting through a column volume of dichloromethane), eluting sequentially with dichloromethane, chloroform, diethyl ether, ethyl acetate,
  • Circular Dichroism ⁇ max 250.2nm ( ⁇ E -1.34M “1 cm “1 ) ⁇ max 285.4nm ( ⁇ E +0.99M “ 1 ), (MeCN/H 2 O)
  • Example 76 (alternative preparation) A mixture of Intermediate 46 (1.056g), cyclopropylamine (0.73ml) and potassium iodide (481 mg) in acetonitrile (25ml) was stirred for 3 hours. The solvent was evaporated in vacuo and the mixture partitioned between sat. sodium bicarbonate solution (20ml) and dichloromethane (20ml). The phases were separated. The aqueous phase was further extracted with dichloromethane (2x20ml) The combined organics were dried (MgSO 4 ), filtered and the solvent removed in vacuo to leave an oil.
  • the aqueous phase was separated and extracted with dichloromethane (150ml). The combined organics were washed with brine (250ml), dried (MgSO ) and concentrated in vacuo to leave a brown solid.
  • the solid was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia 150:8:1 to 135:8:1) to give a cream solid (29.3g).
  • the solid was dissolved in dichloromethane (150ml) and treated with 1.0M. hydrogen chloride in ether (75ml). The solvent was removed in vacuo to leave a solid which was again dissolved in dichloromethane (150ml) and treated with 1.0M.
  • Example 78 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl- oxazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • a stirred suspension of Intermediate 56 (second preparation: 40mg) in dichloromethane (4ml) was treated with oxalyl chloride (63mg) followed by dimethylformamide (1 drop). The reaction mixture was stirred for 1.5h. The solvent was removed in vacuo and replaced by toluene (10 ml). The resultant suspension was triturated vigorously for 10 min.
  • Example 80 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-oxazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid, melting point 156-160°C.
  • Example 82 rel-(3S,3aS,6aR)-4- ⁇ 2-[(Cyclopropyl-methyl-amino)-methyl]-oxazole-4-carbonyl ⁇ -
  • Example 83 was prepared in a similar manner to Example 82 from Intermediate 10 and Intermediate 52:
  • Example 83 rel-(3S,3aS,6aR)-4- ⁇ 2-[(Dicyclohexylamino)-methyl]-oxazole-4-carbonyl ⁇ -3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
  • Example IC 50 ( ⁇ M) Example IC 50 ( ⁇ M)
  • Example ICso ( ⁇ M) Example IC 50 ( ⁇ M)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

There are provided according to the invention compounds of formula (I) wherein R?1, R2 and R3¿ are as defined in the specification. Compounds of formula (I) are useful, inter alia, in the treatment of inflammatory disorders of the respiratory tract.

Description

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
The present invention relates to therapeutically active bicyclic compounds, processes for their manufacture, pharmaceutical formulations containing them and their use in chemotherapy. In particular, we have found a group of novel bicyclic compounds which are effective in treating inflammatory diseases.
Inflammation is a primary response to tissue injury or microbial invasion and is characterised by circulating leukocytes binding to and extravasation through vascular endothelium. Circulating leukocytes include neutrophils, eosinophils, basophils, monocytes and lymphocytes. Different forms of inflammation involve different types of infiltrating leukocytes.
The inflammatory process can be triggered in a number of ways, including by infection, tissue damage and autoimmune reactions. As part of the inflammatory process, neutrophils move from the bloodstream into the tissue at the site of tissue lesion. The neutrophils contain large numbers of different intracellular granules and when activated at the site of inflammation the contents of these granules are secreted into the tissue. The different granules contain a variety of enzymes and other proteins, many of which have antibacterial properties.
One of the enzymes found in the azurophilic granules is neutrophil elastase. Neutrophil elastase has a wide spectrum of activities in the body. For example, within the lung the enzyme increases mucus production and changes the cellular composition of the epithelium The enzyme also causes vascular permeability changes within the microcirculation of many tissues and it is a potent destructive agent against a number of connective tissue components. Although there are within the body endogenous inhibitors of elastase, including the anti-trypsin and the leukocyte protease inhibitor, elastase activity has been implicated in the pathogenesis of a number of disease states including inflammatory diseases of the airways, the joints and the skin. The enzyme is also responsible for some or most of the symptoms of acute respiratory distress syndrome (ARDS) and other acute inflammatory states brought about by trauma and/or sepsis.
We have now found a group of novel compounds which inhibit neutrophil elastase. These compounds are therefore of potential therapeutic benefit in the treatment and amelioration of symptoms of diseases where elastase activity is implicated.
Thus, according to one aspect of this invention, we provide a compound of the formula (I)
(relative stereochemistry indicated) wherein: R1 represents C1-6alkyl;
R2 represents C2-4alkyl or C2- alkenyl;
X represents CO or SO2;
Het represents an optionally substituted 5 to 10 membered monocylic or bicyclic aromatic ring system containing 1 to 4 heteroatoms selected from O, N and S; n represents an integer 0 to 4;
R3 and R4 independently represent hydrogen, C1-8alkyl, -(CH2) CONR5R6, COC^alkyl or (CH2)0-2 Ph where Ph represents phenyl optionally substituted by one or more C1-4alkyl or halogen groups or NR3 R4 together represents azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, morpholinyl, piperazinyl optionally N- substituted by C1-6alkyl, phenyl (optionally substituted by halogen or C1-4alkyl) or benzyl (optionally substituted on the benzene ring by halogen or C1-4alkyl) or NR3R4 together represents a ring as just described save that it is substituted on carbon by one or more C^alkyl, CONR5R6 or COOR6 groups; R5 and R6 independently represent hydrogen or C1-4alkyl; and salts and solvates thereof (hereinafter "compounds of the invention").
Formula (I) shows the relative stereochemistry of the chiral centres. The invention embraces compounds of the invention in racemic form as well as in a form in which one enantiomer predominates or is present exclusively. Generally, we prefer to provide a compound of formula (I) in enantiomerically pure form, most particularly the enantiomer having the absolute stereochemistry illustrated in formula (I).
The present invention also covers the physiologically acceptable salts of the compounds of formula (I). Suitable physiologically acceptable salts of the compounds of formula (I) include inorganic and organic acid salts such as hydrochloride and tartrate.
When used herein "alkyl" includes branched as well as straight chain alkyl and may also include cycloalkyl when 3 or more carbon atoms are present.
Suitable R^ alkyl groups include methyl, ethyl and propyl. Examples of Het groups include furanyl, imidazolyl, thiophenyl, pyrrolyl, thiazolyl, isoxazolyl, pyrazolyl, pyridinyl and pyrazinyl.
Het may be connected to the pyrrolidine ring via X in any position. Examples of connectivities include furan-2-yl, furan-3-yl, imidazol-2-yl, imidazol-4-yl, thiophen-2-yl, pyrrol-2-yl, thiazol-4-yl, isoxazol-3-yl, pyrazol-3-yl, pyrazol-5-yl, pyridin-3-yl, l-methyl-pyrrol-2-yl, 1-methyl-pyrazol-3-yl, 1-methyl-pyrazol-5-yl and pyrazin-2-yl.
Examples of substituents for Het include C1-6alkyl (e.g. methyl, ethyl), C^alkoxy (e.g. methoxy), nitro and halogen (e.g. chlorine, bromine, fluorine, iodine). The substituent(s) may be on carbon or nitrogen.
Examples of substituted Het include 1 -methyl pyrrolyl, 1 -methyl pyrazolyl.
Examples of positions for the sidechain shown in formula (I) include for furan-2- yl the 5 position, for furan-3-yl the 2 position, for thiophen-2-yl the 5 position, for pyrrol-2-yl the 4 or 5 position, for 1 -methyl pyrrol-2-yl the 5 position, for thiazol-4- yl the 2 position, for isoxazol-3-yl the 5 position, for 1-methyl-pyrazol-3-yl the 5 position, for 1-methyl-pyrazol-5-yl the 3 position, for pyridin-3-yl the 6 position and for pyrazin-2-yl the 5 position.
When R3 and R4 independently represent C1-8alkyl, examples include methyl, ethyl, cyclopropyl, n-propyl, isopropyl, n-butyl, CH(iPr)2 and cyclohexyl.
When R3 and R4 independently represent (CH2)0-2Ph, examples include phenyl, benzyl and (4-F-phenyl)methyl. When NR3R4 together represents N-substituted piperazinyl, examples include N- phenyl-piperazinyl and N-methyl-piperazinyl.
When NR3R4 together represents a ring substituted on carbon, examples of substituents include methyl, CONH2 and COOMe. Examples of such NR3R4 include 4-methyl piperidin-1-yl.
We prefer R1 to represent methyl or ethyl, especially methyl.
We prefer R2 to represent isopropyl or propyl, especially isopropyl.
We prefer X to represent CO.
We prefer Het to represent a 5 or 6 membered monocyclic aromatic ring containing 1 or 2 heteroatoms selected from O, N and S which is more preferably thiazolyl, isoxazolyl, pyrazolyl or pyrazinyl, especially thiazolyl (particularly thiazol-4-yl) or pyrazinyl.
We also prefer Het to represent pyridinyl, especially 3-pyridinyl.
We most especially prefer Het to represent pyrazinyl. Ideally Het represents pyrazin-2-yl in which the sidechain is in the 5-position.
We also prefer Het to represent oxazolyl, particularly oxazol-4-yl.
We prefer n to represent 1 to 3, particularly 1 or 2, especially 1.
We prefer R3 and R4 independently to represent hydrogen or Chalky! or for NR3R4 to represent pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl optionally N-substituted by C1-8alkyl or phenyl (optionally substituted by halogen or C1-4alkyl). When R3 and R4 independently represent hydrogen or C^alkyl, preferred NR3R4 groups are NMe2, N(n-butyl)2, NHMe NH(cyclopropyl), NHCH(iPr)2 and N(cyclohexyl)2.
A set of compounds of formula (I) of particular interest are compounds of formula (IA) in which Het represents oxazol-4-yl with the sidechain in the 2- position:
(relative stereochemistry indicated) wherein R4, R3, n, X, R2 and R1 are as defined above.
We prefer X to represent CO. We prefer R to represent isopropyl or propyl, especially isopropyl. We prefer R1 to represent methyl or ethyl, especially methyl. We prefer n to represent 1 to 3, particularly 1 or 2, especially 1. We prefer R3 and R4 independently to represent hydrogen or C^alkyl or for NR3R4 to represent pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl optionally N- substituted by C1-8alkyl or phenyl (optionally substituted by halogen or C1-4alkyl). We particularly prefer -NR3R4 to represent pyrrolidinyl, piperidinyl, N- phenylpiperazinyl, N(butyl)2, NMe(cyclopropyl) or N(cyclohexyl)2, most particularly pyrrolidinyl. The potential for compounds of the invention to inhibit neutrophil elastase activity may be demonstrated, for example, using the following in vitro and in vivo assays:
5 In vitro assays of human neutrophil elastase
Assay contents:
50mM Tris/HCI (pH 8.6)
10 150mM NaCI
11.8nM purified human neutrophil elastase
Suitable concentrations of compound under test diluted with water from a 10mM stock solution in dimethylsulphoxide. Values above are final concentrations after the addition of substrate solution (see below).
15
The mixture above is incubated for fifteen minutes at 30 C at which time the remaining elastase activity is measured for 10 minutes in a BioTek 340i plate- reader, after the addition of O.δmM MeO-succinyl-alanyl-alanyl-prolyl-valyl-p- nitroanilide. The rate of increase in absorbance at 405nm is proportional to
20 elastase activity. Enzyme activity is plotted against concentration of inhibitor and an IC50 determined using curve fitting software.
In vivo activity of inhibitors of human neutrophil elastase: An oral in vivo model using IL-8 induced lung infiltrates for the assessment of 25 intracellular elastase inhibition
Adult hamsters (100-150g) are randomised into groups (n=4) and fasted overnight. Under gaseous anaesthetic (3% isofluorane) animals are dosed orally with 1ml_/100g water as vehicle or containing predissolved compounds. Either at the same time, or subsequently under anaesthetic, animals are dosed intratracheally with 1ug recombinant human IL-8 in 100uL sterile saline. Six hours after IL-8 dosing animals are sacrificed using intraperitoneal pentobarbitone. The lungs are lavaged with 2 x 2.5 ml_ sterile saline and femurs are removed by dissection.
Intracellular elastase is prepared from neutrophils collected by lavage and from femoral bone marrow . This is achieved by sonication of the neutrophils and centrifugation to yield intracellular granules. These are disrupted by freeze/thawing and sonication. Elastase and myeloperoxidase assays are then performed on these samples to assess the efficacy of the compounds and to normalise for neutrophil recovery.
Human whole blood elastase inhibition assay
Triplicate aliquots of fresh, heparinised human whole blood (200μl) are added to appropriately diluted samples (10μl) of compounds under test. Control samples (6 replicates) contain water in place of compound. Samples are mixed thoroughly by pipette, and are then incubated for 30 minutes at 37°C. Cold red cell lysis buffer (750μl of 155mM ammonium chloride, 0.12mM EDTA, 10mM potassium bicarbonate, pH 7.4) is then added. Tubes are capped, inverted several times, and maintained at 4°C for 15 minutes, inverting every 5 minutes. After centrifugation at 250g for 10 minutes, at 4°C, the resulting pelleted cells are washed. The wash is with saline (300μl), followed by centrifugation at 100g for 10 minutes at 4°C. Pellets are washed twice more, before resuspension of the final cell pellet in buffer (200μl of 100mM Tris, 300mM NaCI, 1% (w/v) HTAB, pH 8.6). Samples are stored at -20 °C. After freeze-thawing of the samples four times, elastase activity is determined by a colorimetric assay in 50mM Tris, 150mM NaCI, 0.6mM MeO-Succ-Ala-Ala-Ala-Pro-Val-pNA at pH 8.6, measuring the rate of increase in absorbance at 405nm.
Accordingly, the compounds of the invention are of potential therapeutic benefit in the treatment and amelioration of symptoms of diseases where elastase activity is implicated. Such diseases particularly include bronchitis, including chronic bronchitis. Also any chronic obstructive pulmonary disease (COPD).
Examples of disease states in which the compounds of the invention have potentially beneficial effects include inflammatory diseases of the respiratory tract such as bronchitis (including chronic bronchitis), bronchiectasis, asthma and hyper-reactivity states of the lung, acute respiratory distress syndrome and septic shock, inflammatory or destructive conditions of the lung such as emphysema and cystic fibrosis and inflammatory or destructive conditions of external tissue such as skin diseases (e.g. lupus and psoriasis) and periodontal disease including gingivitis.
Further examples of disease states and conditions in which compounds of the invention have potentially beneficial effects include wound healing and treatment of burns, cardiovascular diseases such as myocardial infarction and stroke, peripheral vascular disease including intermittent claudication, atherosclerosis, reperfusion injury, cardiovascular changes occurring during cardiopulmonary bypass surgery and septicemia.
Compounds of the invention may also be useful in the treatment of connective tissue disorders such as rheumatoid arthritis, osteoarthritis and spondylitis and inflammatory conditions of the kidney such as glomerulonephritis. They may also be useful in the treatment of certain leukemias including acute myelogenous leukemia, acute myelomonocytic leukemia and the chronic monocytic leukemias and in prevention or inhibition of metastasis of solid tumours e.g. lung, breast, prostate and stomach cancers and melanomas.
A particular aspect of the present invention is the use of compounds of formula (I) in the treatment of chronic bronchitis. Chronic bronchitis is a condition which results from the exposure of the airway surface to noxious chemicals or agents or is secondary to another disease. The symptoms of the condition are caused by the excessive secretion of mucus onto the surface of the airways. This excess mucus cannot be cleared effectively and the result is reduced gas exchange within the lungs resulting in laboured breathing and hypoxemia, recurrent microbial infections and persistent cough associated with the expectoration of mucoid material. The proposed mechanism for the excessive secretion of mucus involves the recruitment of neutrophils into the airways following the exposure of the epithelium to irritant materials; the neutrophils secrete elastase onto the surface of the airways and the enzyme brings about both an increase in the amount of mucus secreted onto the airway surfaces and a dramatic change in the cellular composition of the airway epithelium. Inhibition of elastase activity by the administration of compounds of this invention is therefore an approach to the treatment of chronic bronchitis. Reduced lung function in COPD (eg in chronic bronchitics with airflow obstruction) is also due to elastase mediated lung damage leading to airway narrowing and inflammation. Thus an elastase inhibitor will improve lung function.
As indicated above, compounds of the invention are useful in human or veterinary medicine, in particular as inhibitors of the enzyme neutrophil elastase. Thus, there is provided as a further aspect of the present invention a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in human or veterinary medicine, particularly in the treatment of conditions where elastase activity is implicated such as chronic bronchitis.
It will be appreciated that references herein to treatment extend to prophylaxis as well as the treatment of established conditions.
According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of conditions where elastase activity is implicated, particularly in chronic bronchitis.
In a further or alternative aspect there is provided a method for the treatment of a human or animal subject with a condition caused or mediated by elastase activity which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.
The compounds according to the invention may be formulated for administration in any convenient way, and the invention therefore also includes within its scope pharmaceutical compositions for use in therapy, comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof in admixture with one or more physiologically acceptable diluents or carriers.
There is also provided according to the invention a process for preparation of such a pharmaceutical composition which comprises mixing the ingredients. The compounds according to the invention may, for example, be formulated for oral, buccal, parenteral, topical or rectal administration.
Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disinteg rants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl £- hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate.
For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner. The compounds may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The compounds according to the invention may also be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative. The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or toxicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.
By topical administration as used herein, we include administration by insufflation and inhalation. Examples of various types of preparation for topical administration include ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).
Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents. Such bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol. Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.
Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1 ,1 ,1,2,3,3,3-heptafluoropropane, 1 ,1 ,1,2- tetrafluorethane, carbon dioxide or other suitable gas.
Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin, may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents such as corticosteroids or NSAIDs, bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline), mucolytic agents, anti- muscarinics, anti-leukotrienes, inhibitors of cell adhesion (e.g. ICAM antagonists), anti-oxidants (eg N-acetylcysteine), lung surfactants and/or antimicrobial and anti-viral agents. The compositions according to the invention may also be used in combination with gene replacement therapy. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutically active agent.
The combination referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof represent a further aspect of the invention.
The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
The compound of the invention may conveniently be administered in amounts of, for example, 0.01 to 50mg/kg body weight, suitably 0.05 to 25mg/kg body weight orally, one or more times a day. The precise dose will of course depend on the age and condition of the patient, the particular route of administration chosen, and the disease being treated. The compound is preferably administered orally for the treatment of bronchitis. Other routes of administration may be needed for other indications, for instance i.v. for ARDS.
The compounds of the invention have useful duration of action.
The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention. A process according to the invention for preparing a compound of formula (I) comprises:
(i) condensation of a compound of formula (II):
(relative stereochemistry indicated)
with a compound R4R3N(CH2)nHetCOOH or an acid derivative thereof such as an acid chloride, activated ester, acid anhydride, or a mixed anhydride or with a compound R4R3N(CH2)nHetXY, where Y is a reactive group such as halogen, e.g. chlorine, or a protected derivative thereof; or
(ii) sulphonylation of a compound of formula (III):
(relative stereochemistry indicated) or a protected derivative thereof with a compound YO2SR1 wherein Y is a reactive group such as halogen, e.g. chlorine; or
(iii) cyclising a compound of formula (IV):
(relative stereochemistry indicated) or a carboxylic acid ester thereof; or (iv) oxidation of a corresponding compound of formula (V)
R1
(relative stereochemistry indicated) wherein Xa is sulphur or SO; or
(v) reaction of a corresponding compound of formula (VI)
(relative stereochemistry indicated) wherein L is a leaving group with a compound of formula R4R3NH; or
(vi) preparation of a compound of formula I in which n represents an integer 1 to 4 by reduction of the product of reaction of a corresponding compound of formula (VII)
(relative stereochemistry indicated) with a compound of formula R4R3NH; or
(vii) preparation of a compound of formula I in which n represents 1 by reaction of a corresponding compound of formula (VIII)
(relative stereochemistry indicated) with formaldehyde or paraformaldehyde together with a compound of formula R4R3NH under acidic conditions; or
(viii) deprotecting a compound of formula (I) which is protected; or
(ix) purifying one enantiomer of the compound of formula (I) from a mixture of enantiomers; and where desired or necessary converting a resultant free base compound of formula I into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form.
Process (i)
The condensation reaction with R4R3N(CH2)nHetCOOH is suitably carried out in the presence of a coupling agent such as 1-(3-N,N-dimethylaminopropyl)-3- ethylcarbodiimide, preferably also in the presence of HOBT, and a solvent such as dichloromethane, DMF, MeCN or tetrahydrofuran at a temperature of suitably between O°C and ambient. When an acid derivative such as the acid chloride, activated ester, acid anhydride, or a mixed anhydride is used, reaction conditions will be modified accordingly, for instance by inclusion of a base. If one or both of R3, R4 represents hydrogen, it will generally be preferred to protect the nitrogen, e.g. with BOC.
With R4R3N(CH2)nHetSO2Y. the reaction is suitably carried out in the presence of a base such as triethylamine and a solvent such as DCM, suitably at 0°C- ambient.
Process (ii)
The sulphonylation reaction is suitably carried out in the presence of LHMDS or
NaH, in a solvent such as tetrahydrofuran at a temperature of suitably between
-78°C to O°C.
When one or both of R3 and R4 represents hydrogen, it may be necessary to protect the nitrogen, e.g. with BOC.
Process (iii)
The cyclisation reaction is suitably carried out in the presence of 2-chioro-1- methylpyridinium iodide, or EDC, in a solvent such as dichloromethane, at a temperature of suitably 0°C - reflux. This reaction may also be performed using a carboxylic acid thioester derivative of the compound of formula (IV). Alternatively, another acid derivative such as an acid halide (e.g. acid chloride) may be used.
Process (iv)
This oxidation reaction may be carried out in conventional manner such as by peracid oxidation.
Process (v) Preferred leaving groups include halogen (such as chlorine, bromine or iodine), mesylate and tosylate. The reaction may be performed by combining the reactants optionally in the presence of a base such as triethylamine or potassium carbonate in an inert solvent such as DMF or MeCN.
Process (vi)
This reaction will take place on combining the reagents in an inert solvent, e.g. DCM at ambient or elevated temperature.
Reduction can be performed in situ using a conventional mild reducing agent such as NaBH3CN or NaBH(OAc)3.
Process (vii)
Reaction of the heterocyclic compound of formula (VIII) with formaldehyde or paraformaldehyde and the amine will take place under standard Mannich conditions, e.g. reflux under acid conditions, typically in acetic acid/ethanol. If the amine is used as an acid salt (e.g. the hydrochloride) the acetic acid may be omitted.
Process (viii) Protecting groups, especially nitrogen protecting groups, and means for deprotection are described in T W Greene "Protective Groups in Organic Synthesis", 2nd Ed (1991) J Wiley & Sons.
Process (ix) Purification of a single enantiomer may be achieved by conventional methods such as chiral chromatography (e.g. chiral HPLC) and crystallisation with a homochiral acid (e.g. tartaric acid). Physiologically acceptable acid salts of the compound of formula (I) such as the hydrochloride or tartrate may be prepared by treating a basic compound of formula (I) with the desired acid.
Intermediate compounds of formula (II) may conveniently be prepared according to the methodology in Scheme I below:
Scheme 1
(IX) methionine (X) (C)
HP,
(XIV)
(h)
Oalkyl
, C02alkyl " Oalkyl
' OSi(alkyl)3
NHCOCF, (XVII)
, NHCOCF,
(XVI)
(XVIII) (i) rel-(2S, 3R)
(j)
Step (a)
This is a conventional protection reaction which, in the case when P2 represents
BOC, may be performed by reacting with (BOC)2O in the presence of base (e.g.
NaOH) in a polar solvent system such as dioxan/water.
Step (b)
This conversion may be performed on treatment with ammonium bicarbonate in the presence of a suitable solvent such as pyridine/DMF and in the presence of
(BOC)2O or suitable equivalent.
Step (c)
This is a conventional protection reaction which, in the case when P1 represents
CBZ, may be performed by reaction with nBuLi followed by CBZ-CI in the presence of an inert solvent such as THF below -50 °C.
Step (d)
This reaction may be performed by treatment with RX where RX is a compound
(e.g. Mel, benzyl iodide or Me2SO4) capable of converting sulphur in the SMe moiety to sulphonium in a suitable solvent, e.g. propanone or acetonitrile. Generally R will represent alkyl or aralkyi and X will represent halide, especially iodide, or sulphate. Protection of the amide is convenient, although not essential, for this reaction.
Step (e) This ring closure reaction may be performed by treatment with Dowex 2 x 8 400 mesh OH" resin in a suitable solvent, e.g. MeCN. Alternatively, the ring closure may be performed by treatment with potassium carbonate in a suitable solvent, e.g. MeCN. Step (f)
Deprotection may be performed in a conventional manner, for example, a BOC protecting group may be removed by treatment with HCI, e.g. in dioxan.
Step (g)
This reaction may be performed by treatment with a trifluoroacetic acid alkyl ester (e.g. the methyl ester) or trifluoroacetic anhydride in the presence of a suitable base e.g. N-methylmorpholine.
Step (h)
This conversion will take place on treating the compound of formula (XV) with a reducing agent e.g. lithium borohydride, followed by treatment with concentrated sulphuric acid in the presence of an alkyl alcohol e.g. ethanol solvent.
Step (i)
The reaction of compounds of formula (XVI) and (XVII) takes place in the presence of a Lewis acid e.g. boron trifluoride dietherate and an inert solvent e.g. dichloromethane or MeCN. The group "alkyl" in Oalkyl and OSi(alkyl)3 generally represents C1-6alkyl. In the compound of formula (XVII), suitable alkyl groups in the silyl alkyl moiety include methyl, isopropyl and t-butyl. Preferred Oalkyl is OEt and preferred OSi(alkyl)3 is OSi(i-Pr)3 or OSi(Me)2(t-Bu). The use of variants of compounds of formula (XVII) in which Oalkyl is replaced by OSi(aIkyl)3 is also envisaged.
Compounds of formula (XVII) may be prepared by treatment of the corresponding carboxylic acid ester (R2CH2COOEt or another alkyl ester, which compounds are either known or may be prepared by known methods) with a strong base (eg LHMDS) followed by a trialkylsilylchloride (such as trimethylsilylchloride) or a trialkylsilyltriflate. Typically the reaction will be performed at low temperature (less than 0 °C) in an inert solvent (such as THF) in the presence of DMPU.
Step (j) This deprotection reaction will take place on treatment with base, such as potassium carbonate.
Step (k)
This ring closure reaction may be performed on treatment with an alkyl Grignard reagent (e.g. t-butylmagnesium choride) in an inert solvent such as THF in the presence of tetramethylethylenediamine at a temperature of -20°C to 25°C.
Step (I)
This is a lactam sulphonylation reaction. It is suitably carried out by reaction with R1SO2-Y, wherein Y is a reactive group, preferably chloro, in the presence of LHMDS, NaH or KH, in a solvent such as THF, at a temperature of suitably -78° to 0°C.
Step (m) This is a N-deprotection reaction, which can suitably be carried out in conventional manner. Thus when P., is CBZ, it is suitably carried out by hydrogenation over Pd (OH)2 catalyst in solvents such as ethyl acetate or THF.
Compounds of formula (XV) may also be prepared by following a route described in Scheme 2: Scheme 2
(XXIII)
(XXII)
(b)
Step (a)
The reaction will proceed under standard conditions for forming alkyl esters, for example by treatment with an alcohol eg methanol in the presence of SOCI2. R13 is suitably a C1-6alkyl group, preferably methyl.
Step (b)
The cyclisation reaction will take place on stirring in water with Dowex 2X8 (preferably 400 mesh).
Step (c)
The TFA protected amine is formed by treating the compound of formula (XXIV) with methyl trifluoroacetate in a polar protic solvent, eg MeOH.
Step (d)
Suitable protecting groups P1 include CBZ. In this case, the compound of formula (XXV) may be treated with a strong base such as LHMDS or nBuLi in an inert solvent such as THF, followed by treatment with CBZ-CI. An alternative route for preparation of compounds of formula (XX) from Scheme 1 is given in Scheme 3:
Scheme 3
(XXVII)
HO (XXVlll)
Scheme 3 continued
(XX)
Step (a)
The compounds of formula (XXVI) are either known compounds or may be made in analogous manner to known compounds. P-, is a N-protecting group, preferably CBZ. Step (a) is a further N-protection reaction. P2 in formula (XXVII) is a different N-protecting group, preferably BOC. When P2 is BOC, the reaction is suitably carried out using BOC2O.
Suitably the reaction is carried out in the presence of a base such as triethylamine or 4-dimethylaminopyridine in a solvent such as ethyl acetate, at temperature of suitably 0°-25° C.
Step (b) This conversion is suitably carried out with pyridinium p-toluenesulfonate, in a solvent such as acetone/water, at a temperature suitably between 25°-75° C.
Step (c) This is a condensation rearrangement reaction suitably carried out using a 2- phenylsulfinyl acetic acid ester (PhSOCH2 CO2R13) and piperidine, in a solvent such as acetonitrile, suitably at ambient temperature.
R13 is suitably a C1-6alkyl group, preferably methyl.
Step (d)
This is a Mitsunobu substitution reaction, using phthalimide, PPh3 and a dialkylazodicarboxylate such as DEAD, in the presence of a solvent such as
THF, at a temperature of suitably 0°-40° C.
Step (e)
This is a deprotection reaction, preferably using a strong acid such as TFA in a solvent such as DCM, at a temperature of suitably 0°-40° C.
R13 is suitably C1-6alkyl, preferably ethyl.
Step (f)
This is a cyclisation reaction, suitably carried out as an intramolecular Michael reaction. Suitably NaH is used, in a solvent such as THF, at a temperature such as 0° - 25° C.
Step (g)
In this step two reactions occur: N-deprotection and re-protection. The phthalimido group is removed suitably with hydrazine hydrate in a solvent such as ethanol at a temperature between 0°C and reflux. Protecting group P3 is incorporated in a conventional manner. When P3 is BOC, this is suitably achieved with BOC2O.
Step (h) The R2 side chain may be introduced by alkylation, using as reactant R2-Y, wherein Y is a reactive group such as bromo or iodo. Thus the reaction is carried out using a base, preferably a strong base such as LHMDS. With LHMDS suitably a cosolvent DMPU in THF is used. Suitable reaction temperatures are -78° to 50°C. Under these conditions the reaction generally takes place with good stereochemical control.
Step (i)
This is an ester hydrolysis reaction, followed by a N-deprotection reaction. The former is carried out in a conventional manner, for example by using KOH in aqueous ethanol, at a temperature of suitably 25°-80°C . The latter is carried out in a conventional manner, for example by using HCI in dioxan, at a temperature of suitably 0°-50°C or, if the protecting group is trifluoroacetate, by treatment with base.
Step (j)
This is a cyclocondensation reaction, suitably carried out in the presence of 2-chloro-1-methylpyridinium iodide and a suitable base such as N, N-diisopropyl ethylamine in a solvent such as dichloromethane, at a temperature of suitably 0°C-reflux. We have also found that it is possible to use the compound of formula (XXXV) as a carboxylic acid ester in which case the ester hydrolysis of step (i) is not necessary. In this case the preferred conditions for the cyclocondensation reaction involve the use of an alkyl Grignard reagent eg t- BuMgCI in THF at a temperature between -20°C and 25°C.
An alternative process for preparation of compounds of formula (XXXIII) is shown in Scheme 4:
Scheme 4 diaminobutyric acid
Step (a)
The compounds of formula (XXXVI) are either known compounds or may be 5 prepared in analogous manner to known compounds. P3 is a protecting group as discussed above, and is suitably BOC. The reaction is suitably carried out using PI FA (phenyl iodosylbis(trifluoroacetate)) and a base such as pyridine in an aqueous solvent, such as aqueous THF, dioxan or acetonitrile. This is the method of Stansfield, C.F. Organic Preparations and Procedures Int., 1990, 10 22(5), 593-603.
Step (b)
P< is a protecting group eg CBZ. This protection reaction may be carried out in a conventional manner. For instance it is suitably carried out in a water miscible solvent such as THF, DMF or dioxan using N-
(benzyloxycarbonyloxy)succinamide, benzyloxycarbonyl chloride, or any suitable source of the benzyloxycarbonyl group, with pH adjustment to alkaline with sodium carbonate.
As an alternative step (b1), the compound of formula (XXXVIII) can be prepared in conventional manner from diaminobutyric acid.
Step (c) This reaction is suitably carried out in two stages. The first stage involves reacting the compound of formula (XXXVIII) at reduced temperature with N- methylmorpholine and then an alkyl chloroformate such as ethyl chloroformate, in an organic solvent such as DCM, dioxan or THF. In the second stage the product is reduced, suitably with sodium borohydride at reduced temperature, such as -20° to 10°C, in a solvent such as THF.
Step (d)
This oxidation reaction may be carried out in any suitable manner, for instance using oxalyl chloride in DMSO and methylene dichloride under nitrogen at reduced temperature, such as -30° to -70°C, followed by triethylamine. The intermediate (XXXX) suitably is not isolated.
Step (e)
This reaction is suitably carried out using a Wittig reagent such as a triphenylphosphorane R13O2CCH=PPh3, or may also be carried out using a phosphonate in a Wadsworth-Emmons reaction.
Step (f) This Michael addition reaction is suitably carried out using LHMDS or other strong base in an organic solvent such as THF, ether or toluene, and preferably a complexing agent such as TMEDA is also present.
The intermediate compounds of formula (III) may be prepared by reacting a deprotected compound of formula (XX) from Scheme 1 with R4R3N(CH2)nHetCOOH or R4R3N(CH2)nHetXY in the manner described above in relation to main process (i) above.
(The initial N- deprotection may be carried out as described above under Scheme 1 Step (m).
The intermediate compounds of formula (IV) may be prepared from a compound of formula (XIX) (with the primary amine suitably protected) in an analogous manner to that described above for preparing a compound of formula (III) from a compound of formula (XX) together with main process (ii) above.
Compounds of formula (V) wherein Xa represents S may be prepared by reaction of a corresponding compound of formula (III) with a compound of formula R1SSR1 under standard conditions for nucleophilic displacement. Compounds of formula (V) wherein Xa represents SO may be prepared by peracid oxidation of a corresponding compound wherein Xa represents S.
Compounds of formula (VI), (VII) and (VIII) may be prepared from compounds of formula (II) following conventional methods known perse. Mesylate and tosylate derivatives may be prepared from the corresponding alcohol following treatment with MeSO2CI or paramethylbenzenesulphonylchloride. Compounds of formula R4R3N(CH2)nHetCOOH or an acid derivative thereof, and R4R3N(CH2)nHetXY are either known or may be prepared by conventional methods known perse.
It will be apparent that Schemes 1 , 2, 3 and 4 may be modified to produce homochiral products by using homochiral starting materials (e.g. S-methionine in Scheme 1 or S-diaminobutyric acid in Scheme 4) or by performing an additional chiral resolution step.
If compounds of formula (XIV) in racemic form are prepared following Scheme 1 from racemic methionine, we have found that the isomers of the compounds of formula (XIV) may be resolved by a dynamic resolution procedure. Thus a racemic compound of formula (XIV) may be treated with homochiral di-p-toluoyl tartaric acid in the presence of 3,5-dichloro-2-hydroxybenzaldehyde as catalyst in an inert solvent, e.g. THF. A homochiral salt of the compound of formula (XIV) results. A compound of formula (XV) may then be produced by subsequent treatment with trifluoroacetic acid methyl ester in the presence of N- methylmorpholine.
Both enantiomers of the compound of formula (XIV) may also be produced from a synthesis based on S-methionine or R-methionine following similar procedures.
It will be apparent to a person skilled in the art that the above synthetic processes for the preparation of compounds of formula (I) may be modified so as to include or omit protecting groups or so as to use alternative protecting groups (for example those described in T W Greene "Protective Groups in Organic Synthesis", 2nd Ed (1991) J Wiley & Sons) in the course of routine optimisation of experimental conditions. Novel chiral intermediates in the above described chiral and resolution sections also form an important aspect of this invention.
Processes for preparation of intermediates are also provided as an aspect of this invention.
The compounds of the invention have the advantage that they may be more efficacious, show greater selectivity, have fewer side effects, have a longer duration of action, be more bioavailable by the preferred route have more attractive pharmacodynamic or pharmacokinetic properties or have other more desirable properties than similar known compounds.
The following non-limiting Examples illustrate the present invention.
ABBREVIATIONS
BOC t-butyloxycarbonyl
CBZ Benzyloxycarbonyl
(BOC)20 Di-tert-butyldicarbonate
THF Tetrahydrofuran
LHMDS Lithium bis (trimethylsilyl)amide
DMPU 1 ,3-dimethyl-3,4,5,6-tetrahydro 2 (1H) pyrimidinone
DMAP 4-dimethylaminopyridine
DMF Dimethylformamide
EDC 1-(3-N,N-dimethylaminopropyl)-3- ethylcarbodiimide
DEAD diethylazodicarboxylate
DCM dichloromethane TMEDA tetramethylethylenediamine
DMSO dimethylsulphoxide
HOBT 1-hydroxybenzotriazole
NaBH(OAc)3 sodium triacetoxyborohydride
In the foregoing Intermediates and Examples, all T.l.c. experiments were performed on silica plates.
Intermediates Intermediate 1
2,4-Diamino-butyric acid methyl ester dihydrochloride
To D,L-diaminobutyric acid dihydrochloride (350g) in methanol (1.61) at 0°C was added thionyl chloride (200ml) over ! h. After reflux for 3h, the solvent was removed in vacuo and the residue tritrurated with toluene (650ml) to give the title compound as a white solid (385g). Mass spec, of free base MH+ (found) 133 MH+ (calculated) 133
Intermediate 2 3-Amino-pyrrolidin-2-one
Intermediate 1 (1g), water (70ml) and Dowex 2x8-400 mesh (16.4ml) were stirred for 1 h. The resin was then filtered and the filtrate concentrated in vacuo to give the title compound as a white solid (0.40g), T.l.c (6:1 ethyl acetate: methanol) Rf 0.07.
Intermediate 3
2,2,2-Trifluoro-N-(2-oxo-pyrrolidin-3-yl)-acetamide
A suspension of Intermediate 2 (181g), methyl trifluoroacetate (218ml) and methanol (2.6I) was suspended for 2h. The solvent was then removed jn vacuo to afford the title compound as a cream solid (355g). Mass spec. MNH4 + (found) 214 MNH4 + (calculated) 214
Intermediate 4
2-Oxo-3-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester To intermediate 3 (3.5g) and tetrahydrofuran (100ml) at -70°C was added LHMDS (20ml). After Vih, benzyl chloroformate (2.8ml) was added. The mixture was warmed to room temperature for 1h and 1M hydrochloric acid (25ml) added. After extraction with ethyl acetate (3x25ml), the combined extracts were washed with 2% ammonia solution, 2M hydrochloric acid and brine then dried (MgSO4 ). After solvent removal, the white solid was recrystallised from ethyl acetate: hexane 5:1 to give the title compound as white crystals (4.2g), T.l.c. (9:1 ethyl acetate: methanol) Rf 0.7.
Intermediate 5 2-Ethoxy-3-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester
To Intermediate 4 (34g) in ethanol (1070ml) at -5°C was added sodium borohydride (9.86g). A solution of 4M hydrogen chloride in 1 ,4-dioxan (20ml) was then added dropwise. Periodically further portions of 4M hydrogen chloride in 1 ,4-dioxan (2x5ml, 1x10ml) and sodium borohydride (2g) were added. After 3h, concentrated sulphuric acid (11ml) was added and the mixture warmed to room temperature for 2h. Saturated aqueous sodium bicarbonate (300ml) was then added and the ethanol and dioxan removed in vacuo. The residue was diluted with water (500ml) and extracted with ethyl acetate (3x500ml). The combined extracts were washed with brine and dried (MgS04). The solvent was removed in vacuo and the residue purified by flash chromatography on silica gel 9385 eluting with ether, to give the title compound as a solid (21 g). Mass spec. MNH4 + (found) 378 MNH4 + (calculated) 378 Intermediate 6 trans-2-(1-Ethoxycarbonyl-2-methyl-propyl)-3-(2,2,2-trifluoro-acetylamino)- pyrrolidine-1-carboxylic acid benzyl ester
Intermediate 5 (10g), ethyl trimethylsilyl isopropylketene acetal (11ml) and dichloromethane (250ml) were cooled to 5°C and boron trifluoride dietherate (17ml) added over %h. After 1h, further boron trifluoride dietherate (3.4ml) and ketene acetal (11ml) were added. After a further 1h, 1M hydrochloric acid (200ml) was added and the organic layer separated and washed with brine and dried (MgS04). Solvent removal in vacuo gave the title compound as an oil (16.7g), T.l.c.(2:1 ether: cyclohexane) Rf 0.18 and 0.27.
Intermediate 7 trans-3-Amino-2-(1-ethoxycarbonyl-2-methyl-propyl)-pyrrolidine-1-carboxylic acid benzyl ester Intermediate 6 (31 g), potassium carbonate (71 g), water (930ml) and ethanol
(930ml) were warmed at 60°C for 3h. The ethanol was removed in vacuo and the aqueous residue extracted with ethyl acetate (3x300ml). The combined extracts were washed with brine and dried (MgSO4) and concentrated jn vacuo to give the title compound as a brown oil (17.5g). Mass spec. MH+ (found)) 349 MH+ (calculated) 349
Intermediate 8 rel-(3R,3aR,6aS)-6-lsopropyl-5-oxo-hexahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester Intermediate 7 (17.5g) in tetrahydrofuran (1,800ml) was cooled to -5°C and 1M t- butylmagnesium chloride in tetrahydrofuran(204ml) was added over VJn. After 2h, 1M hydrochloric acid (250ml) and brine (300ml) were added and the mixture was extracted with ethyl acetate (250ml). After concentrating the extracts to half the volume in vacuo, the extracts were washed with brine and dried (MgSO4). Solvent removal in vacuo followed by trituration with diethyl ether (60ml) gave a white solid. This was recrystallised from ethyl acetate to give the title compound (3.4g). Mass spec. MH+ (found) 303 MH+ (calculated) 303
Intermediate 9 rel-(3R,3aR,6aS)-6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro-pyrrolo[3,2- b]pyrrole-1-carboxylic acid benzyl ester
To a stirred solution of Intermediate 8 (15.01g) in anhydrous tetrahydrofuran (950ml) at -74°C under nitrogen, was added 1.0M LHMDS in tetrahydrofuran (69.5ml) dropwise. After stirring at -74°C for 10 min, the mixture was allowed to warm up to 0°C over 45 min, then left at this temperature for 20 min. It was then cooled to -76°C, treated dropwise with methanesulfonyl chloride (9.61ml) and left to stir at this temperature for 1.5h. It was then warmed to -50°C, quenched with saturated ammonium chloride solution (480ml) and allowed to warm up to room temperature. The mixture was partitioned between water (300ml) and ethyl acetate (750ml), the aqueous layer extracted with further ethyl acetate (750ml), then the combined organic extracts washed with brine (450ml), dried (Na2SO4) and concentrated in vacuo to a cream solid. Purification by flash column chromatography on silica (Merck 9385) eluting with ethyl acetate: cyclohexane (1 :3, 1:2, 1:1 then 3:1) gave the title compound as a white crystalline solid (13.65g). T.l.c. (dichloromethane) Rf 0.22 Mass spec MNH4 + (found) = 398 MNH4 + (calculated) = 398
Intermediate 10 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol- 2-one
A suspension of Intermediate 9 (13.63g) in ethyl acetate (900ml) was added to 20% palladium hydroxide (moist) on carbon (3.16g) and the resulting black suspension stirred vigorously under hydrogen at room temperature for 90 min. The mixture was then filtered through Harboriite J2 and concentrated in vacuo to give the title compound as a fine white powder (8.63g). Tic
(Methanol:dichloromethane 1 :9) Rf 0.50 Mass spec MH+ (found) = 247 MH+
(calculated) = 247
Intermediate 11 rel-5-(6R-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro-(3aS,6aR)-pyrrolo[3,2- b]pyrrole-1-carbonyl)-furan-2-carbaldehyde
To a stirred solution of Intermediate 10 (100mg) in acetonitrile (5ml) was added 5-formyl-2-furoic acid (74mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (156mg). The reaction mixture was stirred for 3 days. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane and saturated sodium bicarbonate solution. The organic layer was washed with brine, dried (MgSO4) and concentrated in vacuo. The residue was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:acetonitrile 9:1) to give the title compound (80mg) as a white solid. Mass spec. MH+ (found) 369 MH+ (calculated) 369.
Intermediate 12 rel-(3R,3aR,6aS)-3-(6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro- pyrrolo[3,2-b]pyrrole-1-carbonyl)-furan-2-carbaldehyde
To a stirred solution of Intermediate 10 (540mg) in acetonitrile (40ml) was added 2-formyl-3-furoic acid (400mg) and 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (841 mg). The reaction mixture was stirred for 16h. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane and saturated sodium bicarbonate solution. The aqueous layer was extracted with dichloromethane. The combined organics were washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:acetonitrile 9:1) to give the title compound (626mg) as a cream solid. Mass spec. MH+ (found) 369 MH+ (calculated) 369.
Intermediate 13 rel-(3R,3aR,6aS)-5-(6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro- pyrrolo[3,2-b]pyrrole-1-carbonyl)-thiophene-2-carbaldehyde To a stirred solution of Intermediate 10 (250mg) in acetonitrile (10ml) was added 5-formylthiophene-2-carboxylic acid (206mg) and 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (389mg). The reaction mixture was stirred for 3h. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane and saturated sodium bicarbonate solution. The aqueous layer was extracted with dichloromethane. The combined organics were washed with brine, dried (MgSO4) and concentrated in vacuo to leave a foam. The foam was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:acetonitrile 9:1) to give the title compound
(280mg) as a cream solid. Mass spec. MH+ (found) 385 MH+ (calculated) 385.
Intermediate 14 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(1H-pyrrole-2-carbonyl)- hexahydro-pyrrolo[3,2-b]pyrrol-2-one
A solution of pyrrole-2-carboxylic acid (60mg), 1-hydroxybenzotriazole (81 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (115mg) and triethylamine (101mg) in dimethylformamide (3ml) was stirred for 5 min. then treated with Intermediate 10 (100mg). The reaction mixture was stirred for 6h. then partitioned between 8% sodium bicarbonate solution (25ml) and ethyl acetate (50ml). The organic phase was separated, washed with water (2x50ml) and the solvent removed in vacuo to leave a solid. A suspension of the solid in diethyl ether (25ml) was stirred for 10 min. then filtered under suction. The residue was dried to give the title compound (123mg) as a white powder. Melting point 200-203°C Mass spec. MH+ (found) 340 MH+ (calculated) 340.
Intermediate 15 rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl- 1 H-pyrrole-2- 5 carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one A solution of 1-methylpyrrole-2-carboxylic acid (150mg), 1-hydroxybenzotriazole (180mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (250mg) and triethylamine (240mg) in dimethylformamide (5ml) was stirred for 15 min. then treated with Intermediate 10 (246mg). The reaction mixture was stirred for
10 18h. then partitioned between 2% sodium bicarbonate solution (135ml) and ethyl acetate (150ml). The organic phase was separated, washed with water (2x120ml), dried (Na2SO4) and the solvent removed in vacuo to leave a semi- solid. The semi-solid was suspended in diethyl ether (20ml) and the suspension was stirred for 10 min. The ether was decanted and replaced by more ether
15 (10ml). The resultant suspension was stirred for 10 min. The ether was again decanted and the residue dried to give the title compound (227mg) as a pale brown solid. Melting point 176-178°C Mass spec. MH+ (found) 354 MH+ (calculated) 354.
20 Intermediate 16
2-(2,2-Dimethyl-propionyloxymethyl)-thiazole-4-carboxylic acid A mixture of α-bromopyruvic acid (1.85g), l-(tert-butylcarbonyloxy) thioacetamide (1.75g) and activated 4 Angstrom molecular sieves (10g) in ethanol (100ml) was stirred for 24h. The solvent was removed in vacuo and
25 replaced by dichloromethane (100ml). The resultant suspension was stirred for 5 min. then filtered through Harboriite J2. The filtrate was evaporated to leave a solid, which was dissolved in ethyl acetate, dried (Na2SO4) and the solvent removed in vacuo to give the title compound (1.83g) as a pale yellow, waxy solid. Melting point 155-158°C Mass spec. MH+ (found) 244 MH+ (calculated) 244.
Intermediate 17
2-Hydroxymethyl-thiazole-4-carboxylic acid A solution of Intermediate 16 (1.78g) and potassium carbonate (1.80g) in methanol (90ml) and water (30ml) was stirred and heated at reflux for 4.5h., cooled, concentrated to 30ml, acidified with 2M hydrochloric acid and extracted with dichloromethane (5x60ml), then concentrated in vacuo to leave a solid which was extracted with a hot (2:1) mixture of industrial methylated spirits and ethyl acetate (2x150ml). These extracts were combined with the dichloromethane extracts and the solvents were removed in vacuo. The residual gum was crystallised from diethyl ether to give the title compound (834mg) as a brown powder. Melting point 121-127°C Mass spec. MH+ (found) 160 MH+ (calculated) 160.
Intermediate 18 rel-(3S,3aS,6aR)-4-(2-Hydroxymethyl-thiazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one
A solution of Intermediate 17 (787mg), Intermediate 10 (1.00g), triethylamine (655mg), 1-hydroxybenzotriazole (718mg) and 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (997mg) in dimethylformamide (5ml) was stirred for 17h. then partitioned between 8% sodium bicarbonate solution (250ml) and ethyl acetate (250ml). The aqueous phase was separated and extracted with ethyl acetate (250ml). The combined organics were washed with 0.5M hydrochloric acid (2x200ml) and water (2x200ml), dried (Na2SO4) and the solvent removed in vacuo to give a foam. The foam was suspended in diethyl ether (100ml), with stirring, for 5 min. The resultant solid suspension was filtered under suction. The residue was dried to leave the title compound (1.23g) as a brown powder. Melting point 197-201 °C Mass spec. MH+ (found) 388 MH+ (calculated) 388.
Intermediate 19 2-Dimethylaminomethyl-thiazole-4-carboxylic acid A mixture of α-bromopyruvic acid (370mg), 1-(dimethylamino)thioacetamide hydrochloride (300mg) and sodium bicarbonate (200mg) in ethanol (25ml) was stirred and heated at reflux for 1.5h. Potassium carbonate (213mg) was added and refluxing was maintained for 0.75h. The reaction mixture was cooled and the solvent was removed in vacuo. The residue was stirred in ethyl acetate (30ml) for 0.5 h. The solvent was decanted. The residual solid was partitioned between 0.5M hydrochloric acid (16ml) and ethyl acetate (20ml). The aqueous phase was separated and concentrated in vacuo to leave a gum. The gum was treated with methanol (20ml) and filtered. The filtrate was concentrated in vacuo and the residue dried to leave the title compound (430mg) as a dark brown powder. Mass spec. MH+ (found) 187 MH+ (calculated) 187.
Intermediate 20 5-Formyl-isoxazole-3-carboxylic acid A solution of ethyl-5-formyIisoxazole-3-carboxylate (25mg) in 1,4-dioxan (3ml) and 2M hydrochloric acid (1ml) was stirred and heated at reflux for 5h.; cooled and the solvents removed in vacuo. The residue was triturated in diethyl ether. The solvent was removed and the residue dried to leave the title compound (18mg) as an orange/brown solid. T.l.c. (dichioromethane:methanol 9:1) Rf = 0.32.
Intermediate 21 rel-(3R,3aR,6aS)-3-(6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro- pyrrolo[3,2-blpyrrole-1-carbonyl)-isoxazole-5-carbaldehyde To a stirred solution of Intermediate 10 (670mg) in acetonitrile (50ml) was added Intermediate 20 (500mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.04g). The reaction mixture was stirred for 4h. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane and saturated sodium bicarbonate solution. The organic phase was separated and passed through a Varian SPE bond elution silica cartridge, eluting sequentially with dichloromethane, chloroform, diethyl ether, ethyl acetate, acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give the title compound (660mg) as a white solid. T.l.c. (dichloromethane:acetonitrile 9:1) Rf = 0.33.
Intermediate 22
1-Methyl-5-styryl-1 H-pyrazole-3-carboxylic acid ethyl ester
A solution of (E)-ethyl-2,4-dioxo-6-phenylhex-5-enoate (40g) and methylhydrazine (9g) in ethanol (250ml) was heated at reflux for 2h. The solvent was removed in vacuo and the residue was purified by flash column chromatography on silica, using a (1 :1) mixture of diethyl ether and cyclohexane as the eluent. Fractions containing the more polar of the two major new components were combined and the solvent evaporated to leave the title compound (25.4g) as yellow crystals. T.l.c. (diethyl ethercyclohexane 1:1) Rf = 0.14.
Also isolated from this reaction was Intermediate 23:
Intermediate 23
2-Methyl-5-styryl-2H-pyrazole-3-carboxylic acid ethyl ester Fractions containing the less polar of the two major new components obtained from the chromatographic purification of Intermediate 22 were combined and the solvent evaporated to leave the title compound (11.4g) as a yellow oil. T.l.c. (diethyl etherxyclohexane 1 :1) Rf = 0.62.
Intermediate 24
5-Formyl-1-methyl-1 H-pyrazole-3-carboxylic acid ethyl ester Ozone was bubbbled through a stirred solution of Intermediate 22 (156mg) in ethyl acetate (10ml) at -78°C for 2h. Nitrogen was then bubbled through the solution, triphenylphosphine (500mg) was added, the solution was warmed to room temperature and the solvent was removed in vacuo. The product was passed through a Varian SPE bond elution silica cartridge, eluting sequentially with dichloromethane, chloroform and diethyl ether. Fractions containing the required product were combined and evaporated to give the title compound (127mg) as white crystals. T.l.c. (diethyl etherxyclohexane 1 :1) Rf = 0.58.
Intermediate 25 5-Formyl-1 -methyl-1 H-pyrazole-3-carboxylic acid
A solution of Intermediate 24 (1.02g) in 1 ,4-dioxan (10ml) and 2M hydrochloric acid (10ml) was stirred and heated at reflux for 24h. The reaction mixture was cooled and the solvent was removed in vacuo to leave the title compound as a pale yellow solid (0.85g). T.l.c. (dichloromethane:methanol 9:1) Rf = 0.19 (streaking).
Intermediate 26 rel-(3R,3aR,6aS)-5-(6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro- pyrrolo[3,2-b]pyrrole-1-carbonyl)-2-methyl-2H-pyrazole-3-carbaldehyde To a stirred solution of Intermediate 10 (783mg) in acetonitrile (60ml) were added Intermediate 25 (645mg) and 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (1.22g). The reaction mixture was stirred overnight. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane and saturated sodium bicarbonate solution. The organic phase was separated and passed through a Varian SPE bond elution silica cartridge, eluting sequentially with dichloromethane, chloroform, diethyl ether and ethyl acetate. Fractions containing the required product were combined and evaporated to give the title compound (315mg) as a white solid. T.l.c. (dichloromethane:acetonitrile 9:1) Rf = 0.24.
Intermediate 27 rel-(3R,3aR,6aS)-5-(6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro- pyrrolo[3,2-b]pyrrole-1-carbonyl)-2-methyl-2H-pyrazole-3-carbaldehyde Ozone was bubbbled through a stirred solution of Intermediate 23 (124mg) in ethyl acetate (15ml) at -78°C for 3h. Nitrogen was then bubbled through the solution, triphenylphosphine (500mg) was added, the solution was warmed to room temperature and the solvent was removed in vacuo. The product was passed through a Varian SPE bond elution silica cartridge, eluting sequentially with dichloromethane, chloroform and diethyl ether. Fractions containing the required product were combined and evaporated to give the title compound (62mg) as white crystals. T.l.c. (diethyl etherxyclohexane 1:1) Rf = 0.70.
Intermediate 28 5-Formyl-2-methyl-2H-pyrazole-3-carboxylic acid
A solution of Intermediate 27 (1.0g) in 1,4-dioxan (10ml) and 2M hydrochloric acid (10ml) was stirred and heated at reflux overnight. The reaction mixture was cooled and the solvent was removed in vacuo to leave the title compound as a pale yellow solid (0.8g). T.l.c. (dichloromethane:methanol 9:1) Rf = 0.54 (streaking).
Intermediate 29 rel-(3R,3aR,6aS)-5-(6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro- pyrrolo[3,2-b1pyrrole-1 -carbonyl)-1 -methyl-1 H-pyrazole-3-carbaldehyde To a stirred solution of Intermediate 10 (812mg) in acetonitrile (45ml) was added Intermediate 28 (660mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.26g). The reaction mixture was stirred for 22h. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane and saturated sodium bicarbonate solution. The organic phase was separated and passed through a Varian SPE bond elution silica cartridge, eluting sequentially with dichloromethane, chloroform, diethyl ether and ethyl acetate. Fractions containing the required product were combined and evaporated to give the title compound (955mg) as a white solid. T.l.c. (dichloromethane.acetonitrile 9:1) Rf = 0.22.
Intermediate 30 6-Bromomethyl-nicotinic acid A mixture of methyl 2-(bromomethyl)pyridine-5-carboxylate (3.8g) and bis(tri- nbutyltin)oxide (16.5ml) in toluene (80ml) was stirred and heated at 80°C for 24h. The reaction mixture was cooled and extracted with 2M hydrochloric acid (2x50ml). The combined aqueous extracts were washed with toluene (40ml) and concentrated in vacuo to leave the title compound (3.0g) as a yellow/brown solid. Mass spec. MH+ (found) 216,218 MH+ (calculated) 216,218.
Intermediate 31 rel-(3R,3aR,6aS)-4-(6-Chloromethyl-pyridine-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one
To a stirred suspension of Intermediate 30 (177mg) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (236mg) in acetonitrile (5ml) was added Intermediate 10 (100mg). The reaction mixture was stirred for 2h. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane (40ml) and 2M sodium carbonate solution (40ml). The organic phase was separated, washed with 2M sodium carbonate solution (20ml) and water (20ml), dried (MgSO4) and concentrated to leave an oil. The oil was purified using flash column chromatography on silica, with dichloromethane:acetonitrile (7:3) as the eluent, to give the title compound (76mg) as a white foam. T.l.c. (dichloromethane:acetonitrile 7:3) Rf = 0.45.
Intermediate 32
5-Bromomethyl-pyrazine-2-carboxylic acid methyl ester
A mixture of Methyl(5-methyl)pyrazine-2-carboxylate (5.3g), N- bromosuccinimide (6.3g) and dibenzoylperoxide (0.33g) in carbon tetrachloride (125ml) was stirred and heated at reflux, with irradiation using a 200W tungsten lamp, for 5h. The reaction mixture was cooled, washed with 10% sodium sulphite solution (2x20ml), water (20ml) and saturated brine (15ml), dried (MgSO4) and concentrated to leave an oil. The oil was purified using flash column chromatography on silica, with cyclohexane:ethyl acetate (3:2) as the eluent, to give the title compound (3.8 g) as a brown solid. T.l.c. (cyclohexane:ethyl acetate 3:2) Rf = 0.28.
Intermediate 33
5-Bromomethyl-pyrazine-2-carboxylic acid hydrochloride A mixture of Intermediate 32 (3.48g) and sodium hydroxide (6.00g) in water (40ml) was stirred for 2h.;acidifιed with 2M hydrochloric acid and extracted with ethyl acetate (4x30ml). The combined extracts were washed with saturated brine (15ml), dried (MgSO4) and the solvent removed in vacuo to leave the title compound (2.58g) as a pale yellow solid. Mass spec. MH+ (found) 217,219 MH+ (calculated) 217,219.
Intermediate 34 rel-(3R,3aR,6aS)-4-(5-Chloromethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one To a stirred solution of Intermediate 10 (800mg) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (934mg) in acetonitrile (10ml) was added Intermediate 33 (1.23g). The reaction mixture was stirred for 18h. The acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane (20ml) and 2M sodium carbonate solution (25ml). The aqueous phase was separated and extracted with dichloromethane (2x20ml). The combined organics were washed with water (15ml) and saturated brine (15ml), dried (MgSO4) and concentrated to leave an oil. The oil was purified using flash column chromatography on silica, with dichloromethane:acetonitrile (7:3) as the eluent, to give the title compound (562mg) as a white foam. T.l.c. (dichloromethane:acetonitrile 7:3) Rf = 0.42.
Intermediate 35 2R-(2,2,2-Trifluoro-acetylamino)-succinamic acid To a stirring suspension of D-Asparagine (37.9g, powdered and dried at 110°C for 48hrs) in methanol (144ml, dried over 3A sieves for 5 hours) under an atmosphere of nitrogen was added triethylamine (40.2ml) followed by methyl trifluoroacetate (36ml). The resulting mixture was left to stir for 48hrs. To the reaction mixture was added dry methanol (145ml) then Dowex 50 resin H+ form (115g, dried at 56°C for 24 hours). The resultant mixture was stirred for 10 minutes, filtered and the solvent removed in vacuo to give a crude white solid containing the title compound. This crude product was combined with crude product from a similar experiment and recrystallised from hot water to afford the title compound as a white crystalline solid (106g). Mass spec MNH4 + (found) 246 MNH4 + (calculated) 246
Intermediate 36 2R-(2,2,2-Trifluoro-acetylamino)-succinamic acid methyl ester A stirring solution of Intermediate 35 (95.14g) in Methanol (1150ml, dried over 3A molecular sieves) was cooled to -70°C. Acetyl chloride (162ml) was slowly added whilst maintaining the reaction temperature below -60°C. The reaction mixture was allowed to warm to -20°C and was left for 48 hours at this temperature. The solvent was removed in vacuo to give a clear and colourless oil containing the title compound. This was triturated with diethyl ether and the resultant white solid was recrystallised from boiling water to afford the title compound as a white crystalline solid (42g). Mass spec MH+ (found) 243 MH+ (calculated) 243
Intermediate 37
3-Cyano-2R-(2,2,2-trifluoro-acetylamino)-propionic acid methyl ester
To a stirring suspension of Intermediate 36 (3.0g) in dichloromethane (20ml) was added pyridine (4.92ml) and p-toluene sulfonyl chloride (4.92g). More dichloromethane (15ml) was added and the brown solution left to stir at room temperature for 48 hours. The reaction mixture was diluted with dichloromethane (25ml), washed with 1M aqueous H3PO4 (74ml), dried (Na2SO4) filtered and the solvent removed in vacuo to give a crude brown solid (3.57g) containing the title compound. The crude mixture was purified by flash chromatography (SiO2, Merck, 9385) eluting with 1:3 then 1:2% ethyl acetatexyclohexane. The eluent was evaporated in vacuo to give the title compound as a white crystalline solid (1.62g). T.L.C (1 :1 Ethyl acetate: cyclohexane) Rf 0.5 Mass spec MNH4 + (found) 242 MNH4 + (calculated) 242
Intermediate 38
2,2,2-Trifluoro-N-(2-oxo-pyrrolidin-3R-yl)-acetamide
A solution of Intermediate 37 (200mg) in ethanol (10ml) was stirred under an atmosphere of hydrogen gas with 5% Rhodium on alumina (1.00g) for 3 hours. The catalyst was removed by filtration and the filtrate concentrated in vacuo to afford a crude gum containing the title compound. The mixture was purified by flash chromatography (SiO2, Merck, 9385) eluting with acetonitrile. The eluent was evaporated in vacuo to afford the title compound as a white solid (40mg). T.L.C (Acetonitrile) Rf 0.63 Mass spec MNH4 + (found) 214 MNH4 +
(calculated) 214
Intermediate 39 2-Oxo-3R-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester To a stirring solution of Intermediate 38 (1.04g) in tetrahydrofuran cooled to - 70°C, was added n-butyl lithium (1.6M in hexanes, 3.31ml). After 5 minutes benzylchloroformate (833μl) was added and the reaction mixture was allowed to warm to room temperature. After 21 hours the reaction mixture was diluted with ethyl acetate (100ml) and washed with 1M hydrochloric acid (2x150ml). The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give a crude orange/white solid which was purified by trituration with diethyl ether to afford the title compound as a white solid (1.25g). Mass spec MNH4 + (found) 348 MNH4 + (calculated) 348 Chiral HPLC (Chiracel AD, eluent system ethanohheptane 15:85, flow rate = 1ml/min). Retention time of R enantiomer = 10.08 min (71.8%). Retention time of S enantiomer = 12.50 min (28.2%)
Intermediate 40
2-Ethoxy-3R-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester
Intermediate 39 (100mg) was dissolved in dry tetrahydrofuran (1ml), cooled to - 20°C and lithium borohydride (2.0M in THF, 0.15ml) added. After 1/2 hour ethanol (1ml) was added followed by concentrated H2SO4 (33μl) and the resultant stirring solution was left at room temperature for 314 hours. The reaction mixture was adjusted to pH8-9 by addition of saturated aqueous sodium bicarbonate and the organic solvents were removed in vacuo. The resultant residue was partitioned between ethyl acetate (20ml) and water (10ml) and the acqueous phase extracted with further ethyl acetate (10ml). The combined organic layers were dried (Na2SO4), filtered and concentrated m vacuo to afford the title compound as a clear oil (101mg) which was used without further purification. Mass Spec. MNH4 + (found) 378 MNH4 +(calculated) 378
Intermediate 40 (Alternative Synthesis)
2-Ethoxy-3R-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1 -carboxylic acid benzyl ester
A solution of Intermediate 39 (214.8g) in dry THF (1200ml) was stirred and cooled to -30°C. Lithium borohydride (2.0M in THF, 336ml) was added (after an initial temperature rise to -12°C, the temperature was maintained below -17°C throughout the addition). The mixture was stirred at -20°C for 90 minutes before ethanol (760ml) was added to the mixture whilst maintaining the temperature below -19°C. A cooled mixture of concentrated sulphuric acid (75ml) in ethanol (215ml) was slowly added to the mixture whilst maintaining the internal temperature below -18°C. The cooling bath was removed and the reaction left to stir for 90 minutes, whereupon the internal temperature had risen to +15°C. A saturated solution of sodium bicarbonate (1600ml) was carefully added to the mixture over 35 min before removal of the volatiles in vacuo. The residual aqueous phase was extracted with ethyl acetate (1000ml + 2x800ml) the combined extracts washed with brine (800ml), dried (Na2S04) overnight and the solvent removed in vacuo to give the title compound (211.6g) as an orange oil. Tic (4:1; CH2C12:Et20) Rf = 0.64 and 0.43
Intermediate 41 (2S,3R)-2-(rel-1S-Ethoxycarbonyl-2-methyl-propyl)-3-(2,2,2-trifluoro- acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester Intermediate 40 (90mg), (1-Ethoxy-3-methyl-but-1-enyloxy)-triisopropyl-silane (Intermediate 95 from International Patent Application No WO97/36903) (0.22g) 5 and dichloromethane (1.1ml) were cooled to 5°C and boron trifluoride dietherate (0.15ml) added. After 55 min the reaction was quenched with 2M aqueous sodium bicarbonate (15ml) and diluted with dichloromethane (10ml). The aqueous layer was separated and the organic layer was washed with a saturated aqueous solution of sodium chloride (10ml). The organic extract was 10 dried (MgSO4), filtered and concentrated in vacuo to afford the title compound as a colourless oil (106mg). Mass spec MH+ (found) 445 MH+
(calculated) 445
Intermediate 41 (Alternative Synthesis)
15 (2S,3R)-2-(rel-1S-Ethoxycarbonyl-2-methyl-propyl)-3-(2,2,2-trifluoro- acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester
Intermediate 40 (97.9g), (Z)-(1-ethoxy-3-methyl-but-l-enyloxyl-triisopropyl-silane) (233g) and dichloromethane (600ml) were cooled to 5°C under nitrogen and boron trifluoride diethyl etherate (200ml) added over 15 minutes. After a further
20 15 minutes, 2M sodium carbonate (750ml) was added, keeping the temperature below 20°C. The reaction mixture was filtered through Hyflo and the solid material washed with dichloromethane (2x200ml). After adding the washes to the 2-phase mixture the aqueous layer was separated and extracted with dichloromethane (2x400ml). The combined extracts were washed with brine
25 (2x250ml), dried (MgSO4) and concentrated in vacuo to give the title compound. (154g). Tic SiO2 (1 :3 ; ethyl acetatexylcohexane) Rf = 0.49 (β-anomer), 0.42 (α-anomer). Mass spec, (found) MH+ = 445 (calc) MH+ = 445
Intermediate 42 (2S,3R)-3-Amino-2-(1-ethoxycarbonyl-2-methyl-propyl)-pyrrolidine-1-carboxylic acid benzyl ester
Intermediate 41 (97mg), potassium carbonate (300mg), ethanol (2ml) and water
(2ml) were warmed at reflux for 2 hours. The ethanol and water were evaporated in vacuo and the residue was partitioned between ethyl acetate
(10ml) and water (10ml). The aqueous extract was taken to pH9-10 by addition of 2M aqueous sodium hydroxide solution and extracted with diethyl ether
(3x20ml). The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to afford the title compound as a clear oil (56mg).
Intermediate 42 (Alternative Synthesis)
(2S,3R)-3-Amino-2-(1-ethoxycarbonyl-2-methyl-propyl)-pyrrolidine-1-carboxylic acid benzyl ester
Intermediate 41 (153g), potassium carbonate (183.3g), ethanol (1000ml) and water (1000ml) were refluxed together for 5h. The organic layer was then separated and concentrated in vacuo. The residue, the aqueous layer and brine
(200ml) were extracted with ether (2x500ml, + 250ml) and the combined extracts extracted with 1M hydrochloric acid (3x500ml). The combined acidic extracts were then taken to pH8 with solid sodium hydrogen carbonate (150g) and extracted with dichloromethane (600ml, + 3x300ml). The combined dichloromethane extracts were dried (MgSO4) and concentrated in vacuo to afford the title compound (87.9g). Tic SiO2 (100:8:1 dichloromethane:ethanol:ammonia) Rf = 0.55 Mass spec (found) MH+ = 349
(calc) MH+ = 349
Intermediate 43
(3aR,6S,6aS)-6-lsopropyl-5-oxo-hexahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester Intermediate 42 (50mg) was dissolved in tetrahydrofuran (1ml) and tetramethylethylenediamine (1ml) then 1M t-butylmagnesium chloride in tetrahydrofuran (0.4ml) added. After stirring for 3 hours the reaction was quenched with saturated ammonium chloride solution (1ml). The aqueous layer was separated and extracted with ethylacetate (4ml). The combined organic extracts were evaporated in vacuo. The residue was partitioned between dichloromethane (10ml) and 2M hydrochloric acid (10ml). The aqueous phase was separated and extracted with dichloromethane (3x5ml). The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give a crude white solid containing the title compound. Purification by flash chromatography (SiO2, Merck, 9385) eluting with 1 :1 ethyl acetatexyclohexane afforded the title compound as a white solid (16mg). T.L.C (2:1 ethyl acetatexyclohexane) Rf 0.38 Chiral HPLC (chiracel AD Column, eluent system ethanol:heptane 10:90, flow rate 1ml/min). Retention time of RRS lactam = 9.92min (73.6%). Retention time of SSR lactam = 13.12min (26.4%)
Intermediate 44
(3aR,6S,6aS)-6-lsopropyl-4-methanesulfonyl-5-oxo-hexahydro-pyrrolo[3,2- b]pyrrole-1-carboxylic acid benzyl ester To Intermediate 43 (0.46g) in dry tetrahydrofuran (30ml) at -70°C under nitrogen was added 1M lithium hexamethyldisilazide in tetrahydrofuran (2.0ml). The solution was warmed to 0°C for 15 minutes and then recooled to -70°C when methane sulphonyl chloride (0.30ml) was added. After 1.5 hours, saturated aqueous ammonium chloride was added (30ml) and the mixture extracted with ethyl acetate (3x5ml). The combined extracts were washed with brine (2x25ml), dried (MgSO4) and the solvent removed in vacuo. Flash chromatography of the residue on silica with 1 :1 ethyl acetatexyclohexane gave the title compound as a white solid (0.34g). T.l.c SiO2(1 :1 ethyl acetatexyclohexane) Rf 0.4 Mass spec MNH4 + (found) = 398 MNH4 + (calculated) = 398 Intermediate 45
(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2- one Intermediate 44 (0.31 g), 10% palladium hydroxide on carbon (0.24g) 1 ,4-dioxan (25ml) and ethyl acetate (25ml) were mixed under hydrogen for 3 hours. The catalyst was then removed by filtration through hyflo and the filtrate concentrated in vacuo to afford the title compound as a pale yellow solid (0.20g). T.l.c SiO2(9:1 chloroform: methanol) Rf = 0.36 Mass spec MH+ (found) = 247 MH+ (calculated) = 247
Intermediate 46
(3S,3aS,6aR)-4-(5-Chloromethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one To a stirred solution of Intermediate 45 (900mg) and 1-(3-dimethylaminopropyl)- 3-ethylcarbodiimide hydrochloride (1.25g) in acetonitrile (25ml) was added Intermediate 1 (1.16g). The reaction mixture was stirred for 1h and further acetonitrile (25ml) was added. The mixture was stirred for 19 hours before the acetonitrile was removed in vacuo and the residue was partitioned between dichloromethane (30ml) and 2M sodium carbonate solution (30ml). The aqueous phase was separated and extracted with dichloromethane (2x30ml). The combined organics were dried (MgSO4), filtered and concentrated to leave a brown foam. The foam was purified using flash column chromatography on silica (Merck 9385), with 20% acetonitrile/dichloromethane as the eluent. The required fractions were evaporated to dryness in vacuo to give the title compound (1.095g) as a white foam. T.l.c. (20% acetonitrile/dichloromethane) Rf = 0.52. Mass spec. MH+ (found) 401 ,403, MH+ (calc) 401,403 Intermediate 47
5-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-pyrazine-2-carboxylic acid Bromine was added to a stirred suspension of 2-methylpyrazin-5-carboxylic acid (60g) in acetic acid (300ml). The reaction mixtire was then heated to 80°C for one hour. The solvent was evaporated in vacuo and the residue partitioned between ethyl acetate (250ml) and 2M aqueous HCI (250ml). The aqueous phase was extracted with further ethyl acetate (5x250ml), the combined organics were washed with 2M HCI (100ml) and saturated brine solution (100ml), dried (MgSO4), filtered and the solvent evaporated in vacuo to leave a brown solid. The solid was stirred in acetonitrile (900ml) and triethylamine (60ml) and cyclopropylamine (30ml) were added. After stirring for 20 hours at room temperature, further cyclopropylamine (30ml) was added and the mixture stirred for a further 15 minutes. The volatiles were evaporated in vacuo, and the residue partitioned between ethyl acetate (200ml) and 2M aqueous HCI (300ml). The organic phase was extracted with further 2M HCI (4x200ml), the combined aqueous extracts were washed with ethyl acetate (50ml), cooled in an ice bath and basified with 10M aqueous sodium hydroxide (120ml). The solution was washed with ethyl acetate (3x200ml) and diethyl ether (200ml), and remaining organic volatiles were removed in vacuo to give a brown aqueous solution. To the solution was added 1 ,4-dioxane (500ml) and di-tert-butyldicarbonate (71g) and the mixture was stirred at room temperature for 20 hours. Further di-tert- butyldicarbonate (10g) was added and stirring continued for a further 24 hours. Citric acid (85g) was added to the stirred mixture before extracting it with ethyl acetate (2x200ml+3x150ml+2x100ml). The combined extracts were dried (MgSO4), filtered and the solvent removed in vacuo to give a brown oil which was purified by flash column chromatography on silica (Merck 9385), with 100:8:1 dichloromethane/methanol/acetic acid as the eluent. The required fractions were evaporated to dryness in vacuo to give a tan coloured solid which was stirred vigorously in 5:1 cyclohexane/diethyl ether until finely divided. The solid was filtered off and dried in vacuo to give the title compound as a orange/brown solid (16.65g).
T.l.c. (100:8:1 dichloromethane/methanol/acetic acid) Rf = 0.31. Mass spec. MH+ (found) 294, MH+ (calc) 294
Intermediate 48
Cyclopropyl-[5-(6S-isopropyl-4-methanesulfonyl-5-oxo-hexahydro-(3aR,6aS)- pyrrolo[3,2-b]pyrrole-1 -carbonyl)-pyrazin-2-ylmethyl]-carbamic acid tert-butyl ester
Intermediate 45 (11.36g), Intermediate 47 (13.53g) and O-(7-azabenzotriazol-1- yl)-Λ/,Λ/,Λ/',Λ/'-tetramethyluronium hexafluorophosphate (19.3g) were stirred in acetonitrile (260ml) at room temperature and N,N-diisopropylethylamine (16ml) added. After stirring for two hours, the solvent was removed in vacuo, the residue diluted with dichloromethane (250ml) and washed with 1M sodium carbonate solution (250ml). The aqueous phase was extracted with dichloromethane (3x150ml). The combined organics were washed with 1M sodium carbonate solution (50ml), dried (MgSO4), filtered and the solvent evaporated in vacuo to leave a yellow-brown solid. The solid was purified by flash column chromatography (Merck 9385 silica) and eluted with 50% ethyl acetate/cyclohexane, and the required fractions evaporated to dryness in vacuo to give the title compound as a white foam (21.55g) Mass spec. MH+ (found) 522, MH+ (calc) 522. [α]D 20 +69.5 (c = 0.8, MeCN)
Intermediate 49:
2-Pyrrolidin-1-ylmethyl-oxazole-4-carboxylic acid ethyl ester
To a stirred solution of 2-(bromomethyl)oxazole-4-carboxylic acid ethyl ester
(43.9g) in acetonitrile (300ml) was added pyrrolidine (15.7ml). After stirring for 10 minutes more pyrrolidine (7.8ml) was added. After a further 30 minutes the solvent was removed in vacuo to leave an orange oil. The oil was partitioned between 1M sodium carbonate (400ml) and dichloromethane (500ml) and the phases were separated. The organic phase was washed with water (100ml), dried (MgSO4), filtered and the solvent removed in vacuo to give the title compound as an orange oil (24.0g). Mass spec MH+ (found) = 225. MH+ (calculated) = 225.
Intermediate 50 2-Pyrrolidin-1-ylmethyl-oxazole-4-carboxylic acid methyl ester
Pyrrolidine (14mg) was added to a suspension of potassium carbonate (25mg) and 2-(bromomethyl)oxazole-4-carboxylic acid methyl ester (27.5mg) in acetonitrile (2.5ml). The reaction mixture was stirred for 6h. The solvent was removed in vacuo. The residue was partitioned between ethyl acetate (15ml) and water (5ml). The organic phase was dried (Na2SO4) and the solvent removed in vacuo to give the title compound (23mg) as a pale brown oil. Mass spec MH+ (found) = 211. MH+ (calculated) = 211.
The following Intermediates 51-55 were prepared in a similar manner to Intermediate 2 from 2-(bromomethyl)oxazole-4-carboxylic acid methyl ester:
Intermediate 51:
2-[(Cyclopropyl-methyl-amino)-methyl]-oxazole-4-carboxylic acid methyl ester hydrochloride Isolated as the hydrochloride: a pale brown gum.
Mass spec MH+ (found) = 211. MH+ (calculated) = 211.
Intermediate 52: 2-[(Dicyclohexylamino)-methyl]-oxazole-4-carboxylic acid methyl ester Pale yellow, waxy solid. Mass spec MH+ (found) = 321. MH+ (calculated) 321.
Intermediate 53: 2-Piperidin-1-ylmethyl-oxazole-4-carboxylic acid methyl ester
Pale brown, waxy solid. Mass spec MH+ (found) = 225. MH+ (calculated) 225.
Intermediate 54: 2-(4-Phenyl-piperazin-1-ylmethyl)-oxazole-4-carboxylic acid methyl ester
Pale yellow, waxy solid. Mass spec MH+ (found) = 302. MH+ (calculated) 302.
Intermediate 55: 2-Dibutylaminomethyl-oxazole-4-carboxylic acid methyl ester
Viscous, pale yellow oil. Mass spec MH+ (found) = 269. MH+ (calculated) 269.
Intermediate 56: 2-Pyrrolidin-1 -ylmethyl-oxazole-4-carboxylic acid/2-Pyrrolidin-1 -ylmethyl- oxazole-4-carboxylic acid potassium salt First Preparation:
Potassium carbonate (14.8g) was added to a solution of Intermediate 49 (24.0g) in ethanol (150ml) and water (150ml). The reaction mixture was refluxed with stirring for 4h. The solvent was removed in vacuo. The orange/brown residue was azeotroped with toluene (x3) and then dried in vacuo. The solid obtained was stirred vigorously with ether (100ml) and filtered off before drying in vacuo to give a mixture of the title compound and potassium bicarbonate as a brown solid (34.5g). This material was used without further purification. Second Preparation:
A solution of Intermediate 50 (22mg) in dioxan (1.5ml) and 1.0M. sodium hydroxide (0.3ml) was stirred for 5.0h. The solution was neutralised (pH ca 7) by the dropwise addition of 2.0M. hydrochloric acid. The solvents were removed in vacuo and the solid residue was dried further in vacuo to give a mixture of the title compound and sodium chloride as a pale yellow solid (40mg). Mass spec MH+ (found) = 197. MH+ (calculated) = 197.
The following Intermediates 57-59 were prepared in a similar manner to Intermediate 56 (second preparation) from Intermediates 53-55 respectively.
Intermediate 57:
2-Piperidin-1 -ylmethyl-oxazole-4-carboxylic acid Cream solid. Mass spec MH+ (found) = 211. MH+ (calculated) = 211.
Intermediate 58:
2-(4-Phenyl-piperazin-1 -ylmethyl)-oxazole-4-carboxylic acid White solid. Mass spec MH+ (found) = 288. MH+ (calculated) = 288.
Intermediate 59:
2-Dibutylaminomethyl-oxazole-4-carboxylic acid
Pale yellow semi-solid. Mass spec MH+ (found) = 255. MH+ (calculated)
255.
Examples
In the foregoing, dihydrochloride salts are indicated by the qualification "(2:1)" after the chemical name.
Example 1 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1-ylmethyl-furan- 2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A mixture of Intermediate 11 (80mg) and pyrrolidine (17mg) in dichloromethane (6ml) was stirred for 2h. Sodium triacetoxyborohydride (69mg) was added and stirring was continued overnight. The reaction mixture was washed with 8% aqueous sodium bicarbonate solution and water. The organic phase was passed through a Varian SPE bond elution silica cartridge (which had been preconditioned by eluting a column volume of dichloromethane), eluting sequentially with dichloromethane, chloroform, diethyl ether, a (1 :1) mixture of diethyl ether and ethyl acetate, ethyl acetate, acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give a gum which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a yellow solid (80mg). Mass Spec MH+ (found) = 424 MH+ (calculated) = 424 T.l.c. (dichloromethane: methanol 9:1): Rf = 0.27.
The following Examples 2-4 were prepared in a similar manner to Example 1 from Intermediate 11 :
Example 2 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- furan-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 440 MH+ (calculated) = 440 T.l.c. (dichloromethane:methanol 9:1): Rf = 0.60.
Example 3 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-furan-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Red solid. Mass Spec MH+ (found) = 515 MH+ (calculated) = 515 T.l.c. (dichioromethane:methanol 9:1): Rf = 0.65.
Example 4 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-methyl-piperazin-1- ylmethyl)-furan-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White solid. Mass Spec MH+ (found) = 453 MH+ (calculated) = 453 T.l.c. (dichloromethane:methanol 9:1): Rf = 0.16.
Example 5 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-morpholin-4-ylmethyl- furan-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A mixture of Intermediate 12 (50mg) and morpholine (13mg) in dichloromethane (3.5ml) was stirred for 1.5h. Sodium triacetoxyborohydride (43mg) was added and stirring was continued overnight. The reaction mixture was diluted with dichloromethane and extracted with 2M hydrochloric acid. The aqueous extracts were made basic with 8% aqueous sodium bicarbonate solution and extracted with dichloromethane. The dichloromethane extracts were washed with brine, dried (Na2SO4) and the solvent removed in vacuo to leave a solid, which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a cream solid (32mg). Mass Spec MH+ (found) = 440 MH+ (calculated) = 440 T.l.c. (dichloromethane:ethanol:ammonia 100:8: 1 ): Rf = 0.68.
The following Examples 6-10 were prepared in a similar manner to Example 5 from Intermediate 12:
Example 6 rel-(3R,3aR,6aS)-4-(2-Dimethylaminomethyl-furan-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 398 MH+ (calculated) = 398 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.70.
Example 7 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-piperidin-1-ylmethyl-furan- 3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Beige solid. Mass Spec MH+ (found) = 438 MH+ (calculated) = 438 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.68.
Example 8 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl-furan- 3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Yellow solid. Mass Spec MH+ (found) = 424 MH+ (calculated) = 424 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.67.
Example 9 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-furan-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Yellow solid. Mass Spec MH+ (found) = 515 MH+ (calculated) = 515 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.86.
Example 10 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-methyl-piperazin-1- ylmethyl)-furan-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 453 MH+ (calculated) = 453 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.50.
Example 11 rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-thiophene-2-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A mixture of Intermediate 13 (60mg), dimethylammonium chloride (36mg) and sodium triacetoxyborohydride (66mg) in dichloromethane (6ml) was stirred overnight. The reaction mixture was diluted with dichloromethane and extracted with 2M hydrochloric acid. The aqueous extracts were washed with dichloromethane then made basic with 2M sodium carbonate solution and extracted with dichloromethane. These dichloromethane extracts were washed with brine, dried (MgSO4) and the solvent removed in vacuo to leave a gum, which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a yellow solid (15mg). Mass Spec MH+ (found) = 414 MH+ (calculated) = 414 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.44.
The following Example 12 was prepared in a similar manner to Example 11 from Intermediate 13:
Example 12 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1-ylmethyl- thiophene-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Yellow solid. Mass Spec MH+ (found) = 454 MH+ (calculated) = 454 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.52.
Example 13 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A mixture of Intermediate 14 (80mg), paraformaldehyde (28mg) and morpholine (40mg) in ethanol (4ml) and glacial acetic acid (1.5ml) was stirred and heated at reflux for 18h. The mixture was cooled to room temperature and partitioned between 8% aqueous sodium bicarbonate solution (25ml) and ethyl acetate (25ml). The aqueous phase was further extracted with ethyl acetate (30ml). The combined organic phases were dried (Na2SO4) and the solvent evaporated in vacuo to leave a gum. The gum was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia 200:8:1) to give a white powder (21 mg) which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a white powder (22mg) Melting Point 184- 188° Mass Spec MH+ (found) = 439 MH+ (calculated) = 439
The following Examples 14-20 were prepared in a similar manner to Example 13 from Intermediate 14:
Example 14 rel-(3S,3aS,6aR)-4-(5-Dimethylaminomethyl-1H-pyrrole-2-carbonyl)-3-isopropyl-
1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
White powder, Melting Point 233-236°C Mass Spec MH+ (found) = 397 MH+ (calculated) = 397
T.l.c. (Dichloromethane:ethanol:ammonia 100:8:1) Rf = 0.45
Example 15 rel-(3S, 3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1 -ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White powder, Melting Point 160-164°C Mass Spec MH+ (found) = 437 MH+ (calculated) = 437
Example 16 rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(5-pyrrolidin-1 -ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White powder, Melting Point 175-178°C Mass Spec MH+ (found) = 423 MH+ (calculated) = 423 Example 17 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-1H-pyrrole-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2) Cream powder, Melting Point 156-160°C
Mass Spec MH+ (found) = 514 MH+ (calculated) = 514
Example 18 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-methyl-piperazin-1- ylmethyl)-1H-pyrrole-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2)
Cream powder, Melting Point 177-181°C Mass Spec MH+ (found) = 452 MH+ (calculated) = 452
Example 19 rel-(3S,3aS,6aR)-4-(5-Dibutylaminomethyl-1 H-pyrrole-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Pale yellow powder, Melting Point 116-120°C
Mass Spec MH+ (found) = 481 MH+ (calculated) = 481
Example 20 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-methylaminomethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Cream powder, Melting Point 210-215°C Mass Spec MH+ (found) = 383 MH+ (calculated) = 383
Example 21 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-piperidin-1- ylmethyl-1H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
A mixture of Intermediate 15 (40mg), paraformaldehyde (15mg) and piperidine (23mg) in ethanol (3ml) and glacial acetic acid (1.5ml) was stirred and heated at reflux for 22h. The mixture was cooled to room temperature and partitioned between 8% aqueous sodium bicarbonate solution (30ml) and ethyl acetate (20ml). The organic phase was dried (Na2SO4) and the solvent evaporated in vacuo to leave a gum. The gum was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia 100:8:1) to give a white solid (26mg) which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a white powder (28mg). Melting Point 149- 153°C Mass Spec MH+ (found) = 451 MH+ (calculated) = 451
The following Examples 22-25 were prepared in a similar manner to Example 21 from Intermediate 15:
Example 22 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-morpholin-4- ylmethyl-1 H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Pale yellow powder, Melting Point 150-154°C Mass Spec MH+ (found) = 453 MH+ (calculated) = 453
Example 23 rel-(3S,3aS,6aR)-4-(5-Dimethylaminomethyl-1-methyl-1H-pyrrole-2-carbonyl)-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White powder, Melting Point 137-141 °C Mass Spec MH+ (found) = 411 MH+ (calculated) = 411 Example 24 rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5-pyrrolidin-1 - ylmethyl-1 H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Yellow powder, Melting Point 135-139°C
Mass Spec MH+ (found) = 437 MH+ (calculated) = 437
Example 25 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5- methylaminomethyl-1H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
White powder, Melting Point 216-218°C
Mass Spec MH+ (found) = 397 MH+ (calculated) = 397
Example 26 rel-(3S,3aS,6aR)-4-(4-Dimethylaminomethyl-1 H-pyrrole-2-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A mixture of Intermediate 14 (80mg), paraformaldehyde (25mg), dimethylammonium chloride (38mg) and activated 4 Angstrom molecular sieves (200mg) in ethanol (10ml) was stirred and heated at reflux for 24h. The mixture was cooled to room temperature and the- solvent was evaporated in vacuo to leave a gum. The gum was purified by flash column chromatography, using two columns (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia; 80:8:1 for the first column, 100:8:1 for the second column) to isolate a white powder (16mg) which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a white powder (16mg). Melting Point 160-165°C Mass Spec MH+ (found) = 397 MH+ (calculated) = 397 T.l.c (dichloromethane:ethanol:ammonia 100:8:1) Rf = 0.20 Example 27 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl- thiazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A solution of Intermediate 18 (387mg) and triethylamine (202mg) in dichloromethane (42ml) was stirred and treated with methanesulphonyl chloride (172mg). The reaction mixture was stirred for 1.5h. An aliquot (7ml) was removed and added to a stirred solution of pyrrolidine (30mg) in dichloromethane (2ml). The solution was stirred for 2 days. Aqueous 8% sodium bicarbonate solution (12ml) was added, with vigorous stirring. The aqueous phase was separated and extracted with dichloromethane (15ml). The organic phases were combined and dried (Na2SO ). The solvent was removed in vacuo to leave a semi-solid, which was triturated in diethyl ether (10ml) to give a solid suspension. Cyclohexane (10ml) was added to the suspension and the solvent was decanted. The residual solid was dried in vacuo to leave a white solid which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a cream powder (51 mg). Melting Point 130-134°C Mass Spec MH+ (found) = 441 MH+ (calculated) = 441
The following Examples 28-35 were prepared in a similar manner to Example 27 from Intermediate 18:
Example 28 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-morpholin-4-ylmethyl- thiazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Pale buff powder, Melting Point 138-143°C Mass Spec MH+ (found) = 457 MH+ (calculated) = 457
Example 29 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-piperidin-1-ylmethyl- thiazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream powder, Melting Point 153-158°C Mass Spec MH+ (found) = 455 MH+ (calculated) = 455
Example 30 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-methyl-piperazin-1- ylmethyl)-thiazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) White powder, Melting Point 153-158°C
Mass Spec MH+ (found) = 470 MH+ (calculated) = 470
Example 31 rel-(3S,3aS,6aR)-4-(2-Cyclopropylaminomethyl-thiazole-4-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Pale grey powder, Melting Point 160-163°C Mass Spec MH+ (found) = 427 MH+ (calculated) = 427
Example 32 rel-(3S,3aS,6aR)-4-{2-[(4-Fluoro-benzylamino)-methyll-thiazole-4-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Pale yellow powder, Melting Point 141-145°C Mass Spec MH+ (found) = 495 MH+ (calculated) = 495
Example 33 rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-thiazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2)
Cream powder, Melting Point 156-161 °C Mass Spec MH+ (found) = 532 MH+ (calculated) = 532
Example 34 rel-(3S,3aS,6aR)-4-(2-Dibutylaminomethyl-thiazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Pale yellow powder, Melting Point 81-86°C Mass Spec MH+ (found) = 499 MH+ (calculated) = 499
Example 35 rel-(3R,3aR,6aS)-3-lsopropyl-4-{2-[(1-isopropyl-2-methyl-propylamino)-methyl]- thiazole-4-carbonyl}-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Cream powder, Melting Point 192-195°C Mass Spec MH+ (found) = 485 MH+ (calculated) = 485
Example 36 rel-(3S,3aS,6aR)-4-(2-Dimethylaminomethyl-thiazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Oxalyl chloride (127mg) was added to a stirred suspension of Intermediate 19 (125mg) in dichloromethane (10ml), followed by dimethylformamide (1 drop). The reaction mixture was stirred for 1.0h. then concentrated in vacuo. The residue was suspended in dichloromethane (15ml) and treated, with stirring, with Intermediate 10 (43mg) and sodium bicarbonate (175mg). After stirring the reaction mixture for 16h aqueous 8% sodium bicarbonate solution (12ml) was added. The aqueous phase was separated and extracted with dichloromethane (15ml). The combined organic extracts were dried (Na2SO4) and evaporated to give a brown gum. The gum was chromatographed on silica (Merck 9385), using a mixture of dichloromethane, ethanol and ammonia (160:8:1) as the eluent, to give a brown gum, which was treated with 1.0M. hydrogen chloride in ether to give the title compound (23mg) as a cream solid. Melting Point 122-127°C Mass Spec MH+ (found) = 415 MH+ (calculated) = 415
Example 37 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A mixture of Intermediate 21 (50mg) and morpholine (13mg) in dichloromethane (5ml) was stirred for 1.5h. Sodium triacetoxyborohydride (43mg) was added and stirring was continued for 2.5h. The reaction mixture was washed with 8% aqueous sodium bicarbonate solution. The organic phase was passed through a Varian SPE bond elution silica cartridge (which had been pre-conditioned by eluting a column volume of dichloromethane), eluting sequentially with dichloromethane, chloroform, diethyl ether, ethyl acetate, acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give a foam which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a white solid (39mg). Mass Spec MH+ (found) = 441 MH+ (calculated) = 441 T.l.c. (dichloromethane:methanol 9:1): Rf = 0.65.
The following Examples 38-44 were prepared in a similar manner to Example 37 from Intermediate 21:
Example 38 rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-isoxazole-3-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White solid. Mass Spec MH+ (found) = 399 MH+ (calculated) = 399 T.l.c. (dichloromethane:methanol 9:1): Rf = 0.58. Example 39 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 425 MH+ (calculated) = 425 T.l.c. (dichloromethane:methanol 9:1): Rf = 0.55.
Example 40 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White solid. Mass Spec MH+ (found) = 439 MH+ (calculated) = 439 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.52.
Example 41 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-methyl-piperazin-1- ylmethyl)-isoxazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
White solid. Mass Spec MH+ (found) = 454 MH+ (calculated) = 454 T.l.c. (dichloromethane:methanol 9:1): Rf = 0.13.
Example 42 rel-(3R,3aR,6aS)-4-{5-[(4-Fluoro-benzylamino)-methyl]-isoxazole-3-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 479 MH+ (calculated) = 479 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.59.
Example 43 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-isoxazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 516 MH+ (calculated) = 516 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.62.
Example 44 rel-(3R,3aR,6aS)-4-(5-Dibutylaminomethyl-isoxazole-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 483 MH+ (calculated) = 483 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.75.
Example 45 rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-1-methyl-1H-pyrazole-3-carbonyl)-
3-isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
A mixture of Intermediate 26 (50mg) and dimethylammonium chloride (32mg) in dichloromethane (5ml) was stirred for 2h. Sodium triacetoxyborohydride (55mg) was added and stirring was continued for 3h. The reaction mixture was washed with 8% aqueous sodium bicarbonate solution. The organic phase was passed through a Varian SPE cartridge (which had been pre-conditioned by eluting through a column volume of dichloromethane), eluting with dichloromethane, chloroform, diethyl ether, ethyl acetate, acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give a pale brown oil which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a cream solid (28mg). Mass Spec MH+ (found) = 412 MH+ (calculated) = 412 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.68.
The following Examples 46-49 were prepared in a similar manner to Example 45 from Intermediate 26: Example 46 rel-(3R,3aR,6aS)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5-pyrrolidin-1 - ylmethyl-1 H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid. Mass Spec MH+ (found) = 438 MH+ (calculated) = 438 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.65.
Example 47 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-morpholin-4- ylmethyl-1 H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Cream solid. Mass Spec MH+ (found) = 454 MH+ (calculated) = 454 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.69.
Example 48 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-piperidin-1- ylmethyl-1 H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Cream solid. Mass Spec MH+ (found) = 452 MH+ (calculated) = 452 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.67.
Example 49 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[1-methyl-5-(4-methyl- piperidin-1-ylmethyl)-1 H-pyrazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2- one hydrochloride
Cream solid. Mass Spec MH+ (found) = 466 MH+ (calculated) = 466 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.78. Example 50 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-methyl-5-(4-phenyl- piperazin-1-ylmethyl)-2H-pyrazole-3-carbonyl1-hexahydro-pyrrolo[3,2-b]pyrrol-2- one hydrochloride A mixture of Intermediate 29 (50mg) and phenylpiperazine (28mg) in dichloromethane (5ml) was stirred for 2h. Sodium triacetoxyborohydride (50mg) was added and stirring was continued overnight. The reaction mixture was washed with 8% aqueous sodium bicarbonate solution. The organic phase was passed through a Varian SPE cartridge (which had been pre-conditioned by eluting through a column volume of dichloromethane), eluting sequentially with dichloromethane, chloroform, diethyl ether, ethyl acetate, acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give a gum which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a dark yellow solid (16mg). Mass Spec MH+ (found) = 529 MH+ (calculated) = 529 T.l.c. (dichloromethane: ethanoLammonia 100:8:1): Rf = 0.77.
The following Examples 51-55 were prepared in a similar manner to Example 50 from Intermediate 29:
Example 51 rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-2-methyl-2H-pyrazole-3-carbonyl)-
3-isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Yellow solid. Mass Spec MH+ (found) = 412 MH+ (calculated) = 412
T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.66.
Example 52 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-methyl-5-pyrrolidin-1- ylmethyl-2H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Yellow solid. Mass Spec MH+ (found) = 438 MH+ (calculated) = 438 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.63.
Example 53 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-methyl-5-morpholin-4- ylmethyl-2H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Yellow solid. Mass Spec MH+ (found) = 454 MH+ (calculated) = 454 T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.65.
Example 54 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-methyl-5-piperidin-1- ylmethyl-2H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
Yellow solid. Mass Spec MH+ (found) = 452 MH+ (calculated) = 452
T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.65.
Example 55 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-methyl-5-(4-methyl- piperazin-1-ylmethyl)-2H-pyrazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2- one hydrochloride Yellow solid. Mass Spec MH+ (found) = 467 MH+ (calculated) = 467
T.l.c. (dichloromethane:ethanol:ammonia 100:8:1): Rf = 0.29.
Example 56 rel-(3R,3aR,6aS)-4-{6-[(Dicyclohexylamino)-methyl]-pyridine-3-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
(1:2)
A mixture of Intermediate 31 (90mg), dicyclohexylamine (104.6μl), sodium iodide (79mg) and potassium carbonate (169mg) in acetonitrile (2ml) was stirred for 5 days. The solvent was evaporated and the residue was partitioned between 2M sodium carbonate solution (2ml) and dichloromethane (3ml). The phases were separated. The organic phase was passed through a Varian SPE cartridge (which had been pre-conditioned by eluting through a column volume of dichloromethane), eluting sequentially with dichloromethane, chloroform, diethyl ether, ethyl acetate, acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give a colourless oil which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a cream solid (60mg). Mass Spec MH+ (found) = 545 MH+ (calculated) = 545 T.l.c. (ethyl acetate): Rf = 0.47.
The following Examples 57-64 were prepared in a similar manner to Example 56 from Intermediate 31:
Example 57 rel-(3R,3aR,6aS)-4-(6-Dibutylaminomethyl-pyridine-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Brown glass. Mass Spec MH+ (found) = 493 MH+ (calculated) = 493 T.l.c. (ethyl acetate) Rf = 0.49
Example 58 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(6-morpholin-4-ylmethyl- pyridine-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Orange glass. Mass Spec MH+ (found) = 451 MH+ (calculated) = 451 T.l.c. (ethyl acetate) Rf = 0.38
Example 59 rel-(3R,3aR,6aS)-4-(6-Cyclopropylaminomethyl-pyridine-3-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Pale brown solid. Mass Spec MH+ (found) = 421 MH+ (calculated) = 421 T.l.c. (ethyl acetate) Rf = 0.36
Example 60 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(6-piperidin-1-ylmethyl- pyridine-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Green solid. Mass Spec MH+ (found) = 449 MH+ (calculated) = 449 T.l.c. (ethyl acetate) Rf = 0.36
Example 61 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[6-(4-methyl-piperazin-1- ylmethyl)-pyridine-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2)
Orange glass. Mass Spec MH+ (found) = 464 MH+ (calculated) = 464 T.l.c. (ethyl acetate) Rf = 0.05
Example 62 rel-(3R,3aR,6aS)-3-lsopropyl-4-{6-[(1-isopropyl-2-methyl-propylamino)-methyl]- pyridine-3-carbonyl}-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2)
Yellow solid. Mass Spec MH+ (found) = 479 MH+ (calculated) = 479 T.l.c. (ethyl acetate) Rf = 0.42
Example 63 rel-(3R,3aR,6aS)-4-(6-Dimethylaminomethyl-pyridine-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Pale yellow glass. Mass Spec MH+ (found) = 409 MH+ (calculated) = 409 T.l.c. (ethyl acetate) Rf = 0.21 5
Example 64 rel-(3R,3aR,6aS)-4-{6-[(4-Fluoro-benzylamino)-methyl]-pyridine-3-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (H2) 10 Yellow/brown solid. Mass Spec MH+ (found) = 489 MH+ (calculated) = 489 T.l.c. (ethyl acetate) Rf = 0.41
Example 65 rel-(3R,3aR,6aS)-4-(5-Cyclopropylaminomethyl-pyrazine-2-carbonyl)-3- 15 isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
A mixture of Intermediate 34 (45mg), cyclopropylamine (23.3μl) and sodium iodide (25mg) in dichloromethane (1ml) was stirred for 18h. More cyclopropylamine (23.3μl) was added and stirring was continued for a further
20 24h. The reaction mixture was partitioned between 2M sodium carbonate solution (3ml) and dichloromethane (3ml). The phases were separated. The organic phase was passed through a Varian SPE cartridge (which had been pre-conditioned by eluting through a column volume of dichloromethane), eluting sequentially with dichloromethane, chloroform, diethyl ether, ethyl acetate,
25 acetonitrile and methanol. Fractions containing the required product were combined and evaporated to give a pale brown oil (17mg) which was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a brown solid (20mg). Mass Spec MH+ (found) = 422 MH+ (calculated) = 422 T.l.c. (ethyl acetate): Rf = 0.12. The following Examples 66-75 were prepared in a similar manner to Example 65 from Intermediate 34:
Example 66 rel-(3R,3aR,6aS)-4-(5-Dibutylaminomethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Pale brown solid. Mass Spec MH+ (found) = 494 MH+ (calculated) = 494 T.l.c. (ethyl acetate) Rf = 0.63
Example 67 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Cream solid. Mass Spec MH+ (found) = 452 MH+ (calculated) = 452 T.l.c. (ethyl acetate) Rf = 0.12
Example 68 rel-(3R,3aR,6aS)-4-{5-[(Dicyclohexylamino)-methyl]-pyrazine-2-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2)
Cream solid. Mass Spec MH+ (found) = 546 MH+ (calculated) = 546 T.l.c. (ethyl acetate) Rf = 0.65
Example 69 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1-ylmethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Cream solid. Mass Spec MH+ (found) = 450 MH+ (calculated) = 450 T.l.c. (ethyl acetate) Rf = 0.12 Example 70 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-methyl-piperazin-1- ylmethyl)-pyrazine-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2) Brown glass. Mass Spec MH+ (found) = 465 MH+ (calculated) = 465 T.l.c. (ethyl acetate) Rf = 0.02
Example 71 rel-(3R,3aR,6aS)-3-lsopropyl-4-{5-[(1-isopropyl-2-methyl-propylamino)-methyl]- pyrazine-2-carbonyl}-1-methanesulfonyl-hexahydro-pyrrolo[3,2-]pyrrol-2-one hydrochloride (1:2)
Cream solid. Mass Spec MH+ (found) = 480 MH+ (calculated) = 480 T.l.c. (ethyl acetate) Rf = 0.45
Example 72 rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Pale brown solid. Mass Spec MH+ (found) = 410 MH+ (calculated) = 410 T.l.c. (ethyl acetate) Rf = 0.06
Example 73 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-pyrazine-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1:2) Pale yellow glass. Mass Spec MH+ (found) = 527 MH+ (calculated) = 527 T.l.c. (ethyl acetate) Rf = 0.27
Example 74 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1-ylmethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Orange/brown solid. Mass Spec MH+ (found) = 436 MH+ (calculated) = 436 T.l.c. (ethyl acetate) Rf = 0.05
Example 75 rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-methylaminomethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride (1 :2) Pale brown solid. Mass Spec MH+ (found) = 396 MH+ (calculated) = 396 T.l.c. (ethyl acetate) Rf = 0.02
Example 76
(3S,3aS,6aR)-4-(5-Cyclopropylaminomethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-blpyrrol-2-one hydrochloride A solution of Intermediate 48 (21.53g) and 4.0M HCI in 1 ,4-dioxan (200ml) was stirred at room temperature for 2 hours. The solvent was removed in vacuo to give an off-white solid. The solid was recrystallised from hot 5% water/2- propanol (2.3I) to give the title (single enantiomer) compound (15.54g) as a white solid. T.l.c. (Silica, eluent 200:8:1 dichloromethane:ethanol:0.880 ammonia) Rf = 0.21. Mass spec. MH+ (found) 422.19, MH+ (calc) 422.19 [α]D 20 +51.3 (c = 0.9, 1 :1 H2O/MeCN)
M.pt. 183-185°C
Circular Dichroism: λmax250.2nm (ΔE -1.34M"1cm"1) λmax285.4nm (ΔE +0.99M" 1), (MeCN/H2O)
Elemental analysis: Found C, 47.4; H, 6.4; N, 14.3; S, 6.5; Cl, 7.8; water, 4.9% (C19H27CI N5O4S .HCI.1.3H2O requires C, 47.4; H, 6.4; N, 14.6; S, 6.7; Cl, 7.4; water, 4.9%).
Example 76 (alternative preparation) A mixture of Intermediate 46 (1.056g), cyclopropylamine (0.73ml) and potassium iodide (481 mg) in acetonitrile (25ml) was stirred for 3 hours. The solvent was evaporated in vacuo and the mixture partitioned between sat. sodium bicarbonate solution (20ml) and dichloromethane (20ml). The phases were separated. The aqueous phase was further extracted with dichloromethane (2x20ml) The combined organics were dried (MgSO4), filtered and the solvent removed in vacuo to leave an oil. The oil was purified by flash column chromatography (Merck 9385 silica) and eluted with 200:8:1 dichloromethane:ethanol:0.880 ammonia. Fractions containing the required product were combined and evaporated to give a white solid (924mg) which was dissolved in dichloromethane (10ml) and treated with 1.0M. hydrogen chloride in diethyl ether (10ml) to give the title (single enantiomer) compound as a white solid (1.00g).
Example 77:
(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl-oxazole- 4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Intermediate 56 (32.2g) was added rapidly to a stirred solution of 1- hydroxybenzotriazole (13.0g) in acetonitrile (350ml). A solution of (3S,3aS,6aR)-3-isopropyl-1-methanesulfonyl-hexahydropyrrolo[3,2-b]pyrrol-2- one (Intermediate 122 from International Patent Application WO97/36903) (21.7g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (37.0g) in acetonitrile (70ml) was then added and the reaction mixture was stirred for 20h. The solvent was removed in vacuo and the residue was partitioned between dichloromethane (900ml) and 1.0M. sodium carbonate solution (600ml). The aqueous phase was separated and extracted with dichloromethane (150ml). The combined organics were washed with brine (250ml), dried (MgSO ) and concentrated in vacuo to leave a brown solid. The solid was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia 150:8:1 to 135:8:1) to give a cream solid (29.3g). The solid was dissolved in dichloromethane (150ml) and treated with 1.0M. hydrogen chloride in ether (75ml). The solvent was removed in vacuo to leave a solid which was again dissolved in dichloromethane (150ml) and treated with 1.0M. hydrogen chloride in ether (75ml). The solvent was removed in vacuo to leave a solid which was recrystallised from acetone to give the title compound (26.3g) as a white solid. Melting point 156-158°C. T.l.c. (Silica; dichloromethane:ethanol:ammonia 100:8:1 ; double elution) Rf = 0.66.
1H_NMR (400 MHz; D-6 DMSO): d 8.78 (s, 1 H), 4.68 (s, 2H), 4.13 (ddd, J= 11 ,11 ,7 Hz, 1 H), 4.08 (dd, J=11 ,10 Hz, 1H), 3.80 (ddd, J=12,10.5,5.5 Hz, 1 H), 3.60 (m, 2H), 3.55 (dd, J=12,10.5 Hz, 1H), 3.31 (s, 3H), 3.20 (m, 2H), 3.03 (dd, J=12,2.5 Hz, 1H), 2.88 (md, J=2.5 Hz, 1H), 2.34 (m, 1H), 2.12 (m, 1 H), 1.96 (m, 4H), 1.19 (d, J=7 Hz, 3H), 0.98 (d, J=7 Hz, 3H). Contains 0.16 Mol. % acetone. Infra-red (KBr diffuse reflectance) 3633, 3474, 3149, 3102, 2956, 2882, 2668, 2576, 2475, 1747, 1709, 1639, 1634, 1567, 1442, 1380, 1347, 1161 , 1146, 967, 810, 547 cm"1. Mass spec MH+ (found) = 425.186372. MH+ (calculated) = 425.185867 (error 1.2ppm).
Combustion analysis.
Found: C, 48.65; H, 6.39; N, 11.41 ; S, 6.19; Cl, 7.13%.
C19H28N4O5S.HCI.0.75H2O.0.2Me2CO requires: C, 48.43; H, 6.57; N, 11.53; S, 6.60; Cl, 7.29%.
Example 78: rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl- oxazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride A stirred suspension of Intermediate 56 (second preparation: 40mg) in dichloromethane (4ml) was treated with oxalyl chloride (63mg) followed by dimethylformamide (1 drop). The reaction mixture was stirred for 1.5h. The solvent was removed in vacuo and replaced by toluene (10 ml). The resultant suspension was triturated vigorously for 10 min. The toluene was removed in vacuo to leave a gum which was suspended in dichloromethane (5 ml) and treated with Intermediate 10 (20mg) and sodium bicarbonate (35mg). The reaction mixture was stirred for 3.75h. then partitioned between dichloromethane (2x10ml) and water (5ml). The combined organics were dried (Na2SO4) and concentrated in vacuo to leave a solid. The solid was triturated in ether (4ml) for 10 min. The ether was decanted. The residue was dried in vacuo to leave a white powder. The powder was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a cream powder (17mg). Melting point 116-120°C. Mass spec MH+ (found) = 425. MH+ (calculated) = 425.
The following Examples 79-81 were prepared in a similar manner to Example 78 from Intermediate 10 and Intermediates 57-59 respectively:
Example 79: rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-piperidin-1-ylmethyl- oxazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
White powder, melting point 140-143°C.
Mass spec MH+ (found) = 439. MH+ (calculated) = 439
Example 80: rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-oxazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride Cream solid, melting point 156-160°C.
Mass spec MH+ (found) = 516. MH+ (calculated) = 516.
Example 81: rel-(3S,3aS,6aR)-4-(2-Dibutylaminomethyl-oxazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride White powder, melting point 122-126°C. Mass spec MH+ (found) = 483. MH+ (calculated) = 483.
Example 82: rel-(3S,3aS,6aR)-4-{2-[(Cyclopropyl-methyl-amino)-methyl]-oxazole-4-carbonyl}-
3-isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
A solution of Intermediate 51 (21 mg) in dioxan (1.5ml) and 1.0M. sodium hydroxide (0.4ml) was stirred for 3.5h. Hydrochloric acid (0.35ml) was added with stirring. The solvents were removed in vacuo. The residue was triturated in dioxan (3ml) for 5 min. The solvent was removed in vacuo. The trituration was repeated using more dioxan (3ml). The solvent was removed in vacuo and the residue dried under vacuum to give a solid. A stirred suspension of this solid in dichloromethane (3ml) was treated with oxalyl chloride (50mg) followed by dimethylformamide (1 drop). The reaction mixture was stirred for 1.0h. The solvent was removed in vacuo and the residue was triturated vigorously in a (1:1) mixture of dichloromethane and toluene (10ml) for 5 min. The solvents were removed in vacuo to leave a gum which was suspended in dichloromethane (5 ml) and treated with Intermediate 10 (18mg) and sodium bicarbonate (35mg). The reaction mixture was stirred for 0.75h., left at room temperature for 3 days, diluted with dichloromethane (10ml) and washed with water (10ml). The organic phase was dried (Na2SO4) and concentrated in vacuo to leave a gum. The gum was purified by flash column chromatography (Merck 9385 silica; eluent dichloromethane:ethanol:ammonia 150:8:1) to give a white powder. The powder was treated with 1.0M. hydrogen chloride in diethyl ether to give the title compound as a white powder (7mg). Melting point 116-119°C. Mass spec MH+ (found) = 425. MH+ (calculated) = 425.
The following Example 83 was prepared in a similar manner to Example 82 from Intermediate 10 and Intermediate 52:
Example 83: rel-(3S,3aS,6aR)-4-{2-[(Dicyclohexylamino)-methyl]-oxazole-4-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride
White powder, melting point 130-133°C.
Mass spec MH+ (found) = 535. MH+ (calculated) = 535.
Biological Data
1. The compounds of Examples 1-83 were tested in the in vitro elastase test described earlier in the description. The IC50 values are given in the following table:
Example IC50 (μM) Example IC50 (μM)
1 0.123 39 0.021
2 0.081 40 0.030
3 0.164 41 0.014
4 0.065 42 0.057
5 0.039 43 0.051
6 0.071 44 0.099 7 7 0 0..008822 4 455 0.019
8 0.086 46 0.014
9 0.129 47 0.024
10 0.114 48 0.030
11 0.139 49 0.051 1 122 0 0..110044 5 500 0.054
13 0.032 51 0.021
14 0.021 52 0.012
15 0.021 53 0.015
16 0.019 54 0.011 1 177 0 0..006688 5 555 0.020
18 0.022 56 0.038
19 0.057 57 0.041
20 0.013 58 0.045
21 0.029 59 0.028 2 222 0 0..004433 6 600 0.037
23 0.026 61 0.030
24 0.024 62 0.041
25 0.009 63 0.025
26 0.017 64 0.048 2 277 0 0..000088 6 655 0.013
28 0.011 66 0.076
29 0.014 67 0.019
30 0.017 68 0.087
31 0.016 69 0.022 3 322 0 0..000099 7 700 0.013
33 0.005 71 0.050
34 0.013 72 0.012
35 0.056 73 0.074
36 0.013 74 0.012 3 377 0 0..001177 7 755 0.093
38 0.014 76 0.011 Example IC50 (μM)
77 0.010
78 0.014
79 0.016
80 0.100
81 0.076
82 0.084
83 0.137
2. Compounds of Examples 1 , 2, 11 , 12, 13, 15, 16, 17, 27, 28, 29, 31 , 33, 34, 35, 37-50, 56, 57, 59, 60, 62-69, 72, 73, 76, 78, 80 and 81 were tested in an in vivo hamster test described above at an effective dose of less than 10mg/kg, and gave a duration of effect lasting at least 6 hours.
3. The compounds of Examples 1 to 83 were tested in the human whole blood elastase inhibition assay described earlier in the description. The IC50 values are given in the table below.
Example ICso (μM) Example IC50(μM)
1 0.355 41 1.76
2 1.882 42 0.43
3 2.195 43 0.429
4 4.185 44 0.528
5 3 45 0.518
6 4.015 46 0.524
7 3.04 47 1.043
8 3.46 48 0.414
9 3.615 49 0.539
10 5.565 50 1.92
11 1.16 51 >10
12 2.4 52 7.637
13 1.103 53 8.23
14 1.885 54 4.205
15 0.452 55 >10
16 0.774 56 0.293
17 0.316 57 0.193
18 2.925 58 2.44
19 0.408 59 0.394
20 6.405 60 0.605
21 0.317 61 5.898
22 0.453 62 0.252
23 0.364 63 1.62
24 0.306 64 0.521
25 1.64 65 0.333
26 >10 66 0.217
26 0.704 67 0.878
28 1.125 68 0.221
29 0.311 69 0.264
30 1.683 70 3.215
31 0.896 71 0.205
32 0.427 72 0.322
33 0.257 73 0.282
34 0.546 74 0.205
35 0.81 75 5.025
36 0.296 76 0.139
37 1.187 77 0.245
38 0.224 78 0.411
39 0.358 79 0.502
40 0.222 80 0.4 Example IC50 (μM)
81 0.296
82 0.717
83 0.55

Claims

Claims
1. A compound of formula (I)
R4R3N(CH2)n-Het \
(relative stereochemistry indicated) wherein:
R1 represents C1-6alkyl; R2 represents C2-4alkyl or C2- alkenyl; X represents CO or SO2;
Het represents an optionally substituted 5 to 10 membered monocylic or bicyclic aromatic ring system containing 1 to 4 heteroatoms selected from O, N and S; n represents an integer 0 to 4; R3 and R4 independently represent hydrogen, C1-8alkyl, -(CH2)1-4CONR5R6, COC1-4alkyl or (CH2)0-2 Ph where Ph represents phenyl optionally substituted by one or more C1-4alkyl or halogen groups or NR3 R4 together represents azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, morpholinyl, piperazinyl optionally N- substituted by C1-6alkyl, phenyl (optionally substituted by halogen or C1-4alkyl) or benzyl (optionally substituted on the benzene ring by halogen or C1-4alkyl) or NR3R4 together represents a ring as just described save that it is substituted on carbon by one or more C1-4alkyl, CONR5R6 or COOR6 groups; R5 and R6 independently represent hydrogen or C1-4alkyl; and salts and solvates thereof.
2. A compound of formula (I) according to claim 1 herein Het represents a 5 or 6 membered monocyclic aromatic ring containing 1 or 2 heteroatoms selected from O, N and S.
3 A compound of formula (I) according to claim 2 wherein Het represents thiazolyl, isoxazolyl, pyrazolyl or pyrazinyl.
4. A compound of formula (I) according to claim 2 wherein Het represents pyridin-3-yl.
5. A compound of formula (I) according to claim 2 wherein Het represents oxazolyl.
6. A compound of formula (I) according to claim 1, 2 or 5 which is a compound of formula (IA)
(relative stereochemistry indicated).
7. A compound of formula (I) according to any one of the preceding claims wherein R2 represents isopropyl or propyl.
8. A compound of formula (I) according to to any one of the preceding claims wherein R2 represents isopropyl.
9. A compound of formula (I) according to any one of the preceding claims wherein R1 represents methyl or ethyl.
10. A compound of formula (I) according to claim 9 wherein R1 represents methyl.
11. A compound of formula (I) according to any one of the preceding claims wherein X represents CO.
12. A compound of formula (I) according to any one of the preceding claims wherein n represents 1 to 3.
13. A compound of formula (I) according to any one of the preceding claims wherein R3 and R4 independently represent hydrogen or C1-8alkyl or NR3R4 represents pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl optionally N- substituted by C1-8alkyl or phenyl (optionally substituted by halogen or C^alkyl).
14. A compound of formula (I) according to claim 1 which is rel-(3R,3aR,6aS)-3-lsopropyl-1 -methanesulfonyl-4-(5-pyrrolidin-1 -ylmethyl-furan-
2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- furan-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-furan-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-methyl-piperazin-1- ylmethyl)-furan-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-morpholin-4-ylmethyl- furan-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(2-Dimethylaminomethyl-furan-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-piperidin-1-ylmethyl-furan-
3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl-furan- 3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-furan-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-methyl-piperazin-1- ylmethyl)-furan-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-thiophene-2-carbonyl)-3-isopropyl-
1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1-ylmethyl- thiophene-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(5-Dimethylaminomethyl-1H-pyrrole-2-carbonyl)-3-isopropyl-
1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(5-piperidin-1 -ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1 -ylmethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-1 H-pyrrole-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-[5-(4-methyl-piperazin-1 - ylmethyl)-1H-pyrrole-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(5-Dibutylaminomethyl-1 H-pyrrole-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(5-methylaminomethyl-1 H- pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5-piperidin-1 - ylmethyl-1 H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-morpholin-4- ylmethyl-1H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(5-Dimethylaminomethyl-1 -methyl-1 H-pyrrole-2-carbonyl)-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5-pyrrolidin-1 - ylmethyl-1 H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5- methylaminomethyl-1H-pyrrole-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2- one; rel-(3S,3aS,6aR)-4-(4-Dimethylaminomethyl-1H-pyrrole-2-carbonyl)-3-isopropyl- 1 -methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl- thiazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-morpholin-4-ylmethyl- thiazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1 -methanesulfonyl-4-(2-piperidin-1 -ylmethyl- thiazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-methyl-piperazin-1- ylmethyl)-thiazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(2-Cyclopropylaminomethyl-thiazole-4-carbonyl)-3-isopropyl- 1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-{2-[(4-Fluoro-benzylamino)-methyl]-thiazole-4-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-thiazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(2-Dibutylaminomethyl-thiazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-4-{2-[(1-isopropyl-2-methyl-propylamino)-methyl]- thiazole-4-carbonyl}-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(2-Dimethylaminomethyl-thiazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-isoxazole-3-carbonyl)-3-isopropyl-
1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1-ylmethyl- isoxazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1 -methanesulfonyl-4-[5-(4-methyl-piperazin-1 - ylmethyl)-isoxazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-{5-[(4-Fluoro-benzylamino)-methyl]-isoxazole-3-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-phenyl-piperazin-1- ylmethyl)-isoxazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrroI-2-one; rel-(3R,3aR,6aS)-4-(5-Dibutylaminomethyl-isoxazole-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-1-methyl-1H-pyrazole-3-carbonyl)-
3-isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-pyrrolidin-1- ylmethyl-1H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(1-methyl-5-morpholin-4- ylmethyl-1H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1 -methanesulfonyl-4-(1 -methyl-5-piperidin-1 - ylmethyl-1 H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[1-methyl-5-(4-methyl- piperidin-1-ylmethyl)-1H-pyrazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2- one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-methyl-5-(4-phenyl- piperazin-1-ylmethyl)-2H-pyrazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2- one; rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-2-methyl-2H-pyrazole-3-carbonyl)-
3-isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-methyl-5-pyrrolidin-1- ylmethyl-2H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-methyl-5-morpholin-4- ylmethyl-2H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(2-methyl-5-piperidin-1- ylmethyl-2H-pyrazole-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[2-methyl-5-(4-methyl- piperazin-1-ylmethyl)-2H-pyrazole-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2- one; rel-(3R,3aR,6aS)-4-{6-[(Dicyclohexylamino)-methyl]-pyridine-3-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(6-Dibutylaminomethyl-pyridine-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(6-morpholin-4-ylmethyl- pyridine-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(6-Cyclopropylaminomethyl-pyridine-3-carbonyl)-3-isopropyl-
1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(6-piperidin-1-ylmethyl- pyridine-3-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[6-(4-methyl-piperazin-1- ylmethyl)-pyridine-3-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-4-{6-[(1-isopropyl-2-methyl-propylamino)-methyl]- pyridine-3-carbonyl}-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(6-Dimethylaminomethyl-pyridine-3-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-{6-[(4-Fluoro-benzylamino)-methyl]-pyridine-3-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(5-Cyclopropylaminomethyl-pyrazine-2-carbonyl)-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(5-Dibutylaminomethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-morpholin-4-ylmethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-4-{5-[(Dicyclohexylamino)-methyl]-pyrazine-2-carbonyl}-3- isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-piperidin-1-ylmethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; reI-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-[5-(4-methyl-piperazin-1- ylmethyl)-pyrazine-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-4-{5-[(1-isopropyl-2-methyl-propylamino)-methyl]- pyrazine-2-carbonyl}-1-methanesulfonyl-hexahydro-pyrrolo[3,2-]pyrrol-2-one; rel-(3R,3aR,6aS)-4-(5-Dimethylaminomethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1 -methanesulfonyl-4-[5-(4-phenyl-piperazin-1 - ylmethyl)-pyrazine-2-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-pyrrolidin-1-ylmethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3R,3aR,6aS)-3-lsopropyl-1-methanesulfonyl-4-(5-methylaminomethyl- pyrazine-2-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; or a salt or solvate of any one thereof.
15. A compound of formula (I) according to claim 1 which is (3S,3aS,6aR)-4-(5-Cyclopropylaminomethyl-pyrazine-2-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one or a salt or solvate thereof.
16. A compound of formula (I) according to claim 1 which is rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl- oxazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-piperidin-1-ylmethyl- oxazole-4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-[2-(4-phenyl-piperazin-1- ylmethyl)-oxazole-4-carbonyl]-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-(2-Dibutylaminomethyl-oxazole-4-carbonyl)-3-isopropyl-1- methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-{2-[(Cyclopropyl-methyl-amino)-methyl]-oxazole-4-carbonyl}- 3-isopropyl-1-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one; rel-(3S,3aS,6aR)-4-{2-[(Dicyclohexylamino)-methyl]-oxazole-4-carbonyl}-3- isopropyl-1 -methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrol-2-one or a salt or solvate of any one thereof.
17. A compound of formula (I) according to claim 1 which is (3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl-oxazole- 4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one or a salt or solvate thereof.
18. A compound of formula (I) according to claim 1 which is (3S,3aS,6aR)-3-lsopropyl-1-methanesulfonyl-4-(2-pyrrolidin-1-ylmethyl-oxazole- 4-carbonyl)-hexahydro-pyrrolo[3,2-b]pyrrol-2-one hydrochloride.
19. A purified single enantiomer of a compound of formula (I) according to any one of claims 1 to 14 and 16 having the absolute stereochemistry as illustrated in formula (I).
20. A compound of formula (I) according to any one of claims 1 to 19 for use as a pharmaceutical.
21. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 19 in admixture with one or more physiologically acceptable diluents or carriers.
22. Use of a compound of formula (I) according to any one of claims 1 to 19 in the manufacture of a medicament for the treatment of chronic bronchitis or chronic obstructive pulmonary disease.
23. A method of treatment of chronic bronchitis or chronic obstructive pulmonary disease in a human or animal subject which comprises administering to said human or animal subject an effective amount of a compound of formula (I) according to any one of claims 1 to 19. 5 24. Use of a compound of formula (I) according to any one of claims 1 to 19 in the manufacture of a medicament for the treatment of asthma. 25. A method of treatment of asthma in a human or animal subject which comprises administering to said human or animal subject an effective amount of a compound of formula (I) according to any one of claims 1 to 19. 10 26. A process for preparing a compound of formula (I) as defined in claim 1 which comprises: (i) condensation of a compound of formula (II):
15 (relative stereochemistry indicated)
with a compound R4R3N(CH2)nHetCOOH or an acid derivative thereof such as an acid chloride, activated ester, acid anhydride, or a mixed anhydride or with a compound R4R3N(CH2)nHetXY, where Y is a reactive group such as halogen, e.g. chlorine, or a protected derivative thereof; or 20 (ii) sulphonylation of a compound of formula (III):
(relative stereochemistry indicated) or a protected derivative thereof with a compound YO2SR1 wherein Y is a reactive group such as halogen, e.g. chlorine; or cyclising a compound of formula (IV):
(relative stereochemistry indicated) or a carboxylic acid ester thereof; or (iv) oxidation of a corresponding compound of formula (V)
(relative stereochemistry indicated) wherein Xa is sulphur or SO; or (v) reaction of a corresponding compound of formula (VI)
(relative stereochemistry indicated) wherein L is a leaving group with a compound of formula R4R3NH; or (vi) preparation of a compound of formula I in which n represents an integer 1 to 4 by reduction of the product of reaction of a corresponding compound of formula (VII)
(relative stereochemistry indicated) with a compound of formula R4R3NH; or
(vii) preparation of a compound of formula I in which n represents 1 by reaction of a corresponding compound of formula (VIII)
Het-X
^N
(Mil)
H V so2 R1
(relative stereochemistry indicated) with formaldehyde or paraformaldehyde together with a compound of formula
R4R3NH under acidic conditions; or (viii) deprotecting a compound of formula (I) which is protected; or
(ix) purifying one enantiomer of the compound of formula (I) from a mixture of enantiomers; and where desired or necessary converting a resultant free base compound of formula I into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form. 27. A compound of formula (III)
(relative stereochemistry indicated) wherein R2, R3, R4, n, Het and X are as defined in claim 1 or a protected derivative thereof. 28. A compound of formula (IV)
(relative stereochemistry indicated) wherein R1, R2, R3, R4, n, Het and X are as defined in claim 1 or a carboxylic acid ester thereof. 29. A compound of formula (V)
(relative stereochemistry indicated) wherein R1, R2, R3, R4, n, Het and X are as defined in claim 1 and Xa represents sulphur or SO. 5 30. A compound of formula (VI)
(relative stereochemistry indicated) wherein R1, R2, n, Het and X are as defined in claim 1 and L represents a leaving group. 10 31. A compound of formula (VII)
(relative stereochemistry indicated) wherein R1, R2, Het and X are as defined in claim 1 and n represents an integer 1 to 4. 15 32. A compound of formula (VIII) Het-Xv
R'
(VIII)
N
H I so,
R1
(relative stereochemistry indicated) wherein R1, R2, X and Het are as defined in claim 1.
EP98951348A 1997-09-09 1998-09-07 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase Withdrawn EP1003748A2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9719183.7A GB9719183D0 (en) 1997-09-09 1997-09-09 Compounds
GB9719189 1997-09-09
GB9719183 1997-09-09
GBGB9719189.4A GB9719189D0 (en) 1997-09-09 1997-09-09 New therapeutic method
GB9719290 1997-09-10
GBGB9719290.0A GB9719290D0 (en) 1997-09-10 1997-09-10 Compounds
GB9803611 1998-02-21
GBGB9803611.4A GB9803611D0 (en) 1998-02-21 1998-02-21 Compounds
PCT/EP1998/005609 WO1999012933A2 (en) 1997-09-09 1998-09-07 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Publications (1)

Publication Number Publication Date
EP1003748A2 true EP1003748A2 (en) 2000-05-31

Family

ID=27451698

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98951348A Withdrawn EP1003748A2 (en) 1997-09-09 1998-09-07 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Country Status (24)

Country Link
EP (1) EP1003748A2 (en)
JP (1) JP2001515904A (en)
KR (1) KR20010023766A (en)
CN (1) CN1278820A (en)
AP (1) AP2000001761A0 (en)
AR (1) AR017072A1 (en)
AU (1) AU9741298A (en)
BR (1) BR9812062A (en)
CA (1) CA2303176A1 (en)
CO (1) CO4970719A1 (en)
EA (1) EA200000204A1 (en)
EE (1) EE200000138A (en)
HU (1) HUP0004644A3 (en)
ID (1) ID24452A (en)
IL (1) IL134791A0 (en)
IS (1) IS5391A (en)
MA (1) MA26543A1 (en)
NO (1) NO20001198L (en)
NZ (1) NZ503130A (en)
PE (1) PE107899A1 (en)
PL (1) PL339176A1 (en)
SK (1) SK3192000A3 (en)
TR (1) TR200000907T2 (en)
WO (1) WO1999012933A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905418D0 (en) * 1999-03-09 1999-05-05 Glaxo Group Ltd Process
CA2561945A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
DE102004024772A1 (en) 2004-05-17 2005-12-22 Grünenthal GmbH Substituted 5-aminomethyl-1H-pyrrole-2-carboxamides
TWI355380B (en) 2004-05-27 2012-01-01 Nihon Nohyaku Co Ltd Substituted pyrazinecarboxanilide derivatives or s
JP4853759B2 (en) * 2004-05-27 2012-01-11 日本農薬株式会社 Substituted pyrazinecarboxylic acid anilide derivatives or salts thereof, intermediates thereof, agricultural and horticultural agents, and methods of use thereof
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
DE602005016009D1 (en) 2004-11-23 2009-09-24 Warner Lambert Co 7- (2H-PYRAZOL-3-YL) -3,5-DIHYDROXY-HEPTANIC ACID DERIVATIVES AS HMG-CO-A REDUCTASE INHIBITORS FOR THE TREATMENT OF LIPIDEMIA
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
PL2024367T3 (en) 2006-05-04 2011-05-31 Chiesi Farm Spa Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
WO2009060206A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
BR112022004861A2 (en) 2019-09-17 2022-06-07 Univ Duke Alvestat for use in the treatment of transplant rejection, bronchiolitis obliterans syndrome and transplant versus host disease
US20230190723A1 (en) 2020-04-16 2023-06-22 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
AP823A (en) * 1996-03-28 2000-04-25 Glaxo Group Ltd Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9912933A2 *

Also Published As

Publication number Publication date
HUP0004644A2 (en) 2001-09-28
NO20001198L (en) 2000-05-08
MA26543A1 (en) 2004-12-20
PE107899A1 (en) 1999-11-17
EE200000138A (en) 2001-02-15
CO4970719A1 (en) 2000-11-07
EA200000204A1 (en) 2000-10-30
AP2000001761A0 (en) 2000-03-31
IL134791A0 (en) 2001-04-30
NZ503130A (en) 2001-08-31
JP2001515904A (en) 2001-09-25
CA2303176A1 (en) 1999-03-18
BR9812062A (en) 2000-09-26
AR017072A1 (en) 2001-08-22
PL339176A1 (en) 2000-12-04
CN1278820A (en) 2001-01-03
IS5391A (en) 2000-02-29
ID24452A (en) 2000-07-20
TR200000907T2 (en) 2000-11-21
SK3192000A3 (en) 2001-03-12
WO1999012933A3 (en) 1999-05-27
AU9741298A (en) 1999-03-29
WO1999012933A2 (en) 1999-03-18
HUP0004644A3 (en) 2002-01-28
KR20010023766A (en) 2001-03-26
NO20001198D0 (en) 2000-03-08

Similar Documents

Publication Publication Date Title
EP1003748A2 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
ES2505270T3 (en) JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
CN103936745B (en) Cdk inhibitors
CN104470917B (en) Arylsultam derivatives as RORc modulators
KR101071438B1 (en) PYRAZOLO[1,5-ａ]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS
US5994344A (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
CN105008360B (en) The Pyrazolopyrimidine derivative of therapeutic activity
US20060166964A1 (en) Inhibitors of HCV replication
US20060046983A1 (en) Inhibitors of HCV replication
JP2020519589A (en) Heteroaryl compounds that inhibit G12C mutant RAS protein
RS54645B1 (en) BENZODIAZEPINE AS A BROMODOMEN INHIBITOR
WO2019153080A1 (en) Inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
KR101485199B1 (en) Pyrazolopyrimidine derivative
US6228853B1 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
KR101577314B1 (en) Fused thiazole derivatives as kinase inhibitors
MXPA00002325A (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
WO2000018770A1 (en) Pyrrolopyrrolone derivatives as antiviral agents
EP1015455A1 (en) Pyrrolopyrrolone derivatives
CZ2000877A3 (en) Pyrrolopyrrolone derivatives
HK1195067A (en) Cdk inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000301

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000301;LT PAYMENT 20000301;LV PAYMENT 20000301;MK PAYMENT 20000301;RO PAYMENT 20000301;SI PAYMENT 20000301

17Q First examination report despatched

Effective date: 20010703

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011114

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1026210

Country of ref document: HK